<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002048" GROUP_ID="MUSKEL" ID="474000021810224273" MERGED_FROM="" MODIFIED="2008-09-22 07:05:05 +0200" MODIFIED_BY="Lara Maxwell" REVIEW_NO="C101-R" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-09-22 00:58:54 -0400" MODIFIED_BY="[Empty name]">
<TITLE>Auranofin versus placebo in rheumatoid arthritis</TITLE>
<CONTACT>
<PERSON ID="15002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Suarez-Almazor</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>msalmazor@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Internal Medicine, Ambulatory Treatment and Emergency Care</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 437</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 713 745 4516</PHONE_1>
<PHONE_2/>
<FAX_1>1 713 563 4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-09-22 00:57:50 -0400" MODIFIED_BY="Lara Maxwell">
<PERSON ID="15002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Suarez-Almazor</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>msalmazor@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Internal Medicine, Ambulatory Treatment and Emergency Care</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 437</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 713 745 4516</PHONE_1>
<PHONE_2/>
<FAX_1>1 713 563 4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5452" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Carol</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Spooner</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>cspooner@ualberta.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Emergency Medicine</DEPARTMENT>
<ORGANISATION>1G1.52 Walter Mackenzie Health Centre</ORGANISATION>
<ADDRESS_1>8440 - 112 ST</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edmonton</CITY>
<ZIP>T6G 2B7</ZIP>
<REGION>Alberta</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 780 407-7576</PHONE_1>
<PHONE_2/>
<FAX_1>+1 780 407-3314</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9254" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Elaine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Belseck</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ebelseck@cha.ab.ca</EMAIL_1>
<EMAIL_2>ebelseck@cha.ab.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>University of Alberta</ORGANISATION>
<ADDRESS_1>2C3.67 Walter C Mackenzie</ADDRESS_1>
<ADDRESS_2/>
<CITY>Alberta</CITY>
<ZIP>T6G 2R7</ZIP>
<REGION/>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 780 492 1078</PHONE_1>
<PHONE_2/>
<FAX_1>+1 780 407 8538</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5440" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Beverley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shea</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bevshea@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart St.</ADDRESS_1>
<ADDRESS_2>Room 312</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562 5800 ext: 8571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-22 00:58:45 -0400" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="22" MONTH="2" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="2" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2002"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-22 00:58:18 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-22 00:58:18 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. C101-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-22 00:58:54 -0400" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Alberta Hospitals Foundation</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-22 01:00:08 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-22 01:00:08 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-22 01:00:08 -0400" MODIFIED_BY="[Empty name]">Auranofin for the treatment of rheumatoid arthritis</TITLE>
<SUMMARY_BODY>
<P>The objective of this review was to evaluate the short-term efficacy of auranofin for the treatment of rheumatoid arthritis when compared to placebo. Our results show that auranofin appears to be efficacious in the short-term treatment of patients with RA (6 months), and has a small but clinically and statistically significant benefit on the disease activity of these patients. Its effects on overall health status and radiological progression are not clear at this time, but would appear to be modest. Auranofin may be most appropriate for those patients with early and mild disease who are more likely to respond to less potent (and less toxic) therapies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Auranofin is an oral gold compound used for the treatment of rheumatoid arthritis (RA). The use of auranofin has declined in the past few years, perhaps due in part to conflicting results from different studies.<BR/> </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To estimate the short-term efficacy and toxicity of auranofin for the treatment of (RA)</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>An electronic literature search was conducted using MEDLINE and EMBASE, followed by hand searches of the reference lists of the trials retrieved from the electronic search.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized controlled trials (RCTs) and controlled clinical trials (CCTs) comparing auranofin against placebo in patients with RA</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The methodological quality of the trials was assessed using Jadad's score. Rheumatoid arthritis outcome measures were extracted from the publications for the 6-month endpoint. The pooled analysis was performed using standardized mean differences (SMDs) for joint counts, pain and global assessments. The weighted mean difference (WMD) was used for ESR. Toxicity was evaluated with pooled odds ratios for withdrawals and adverse reactions. A chi-square test was used to assess heterogeneity among trials. Fixed effects models were used throughout.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>A statistically significant benefit was observed for auranofin when compared to placebo for tender joint scores, pain, patient and physician global assessments and ESR. The standardized weighted mean difference between treatment and placebo was -0.39 (95% CI -0.54, -0.25) for tender joint scores, -0.08 (95% CI -0.22, -0.07) for swollen joint scores, and the weighed mean difference was -4.68 (95% CI -6.59, -2.77) for pain scores. The WMD for ESR was -9.85mm (95% CI -16.46, -3.25). Withdrawals from adverse reactions were 1.5 times higher in the auranofin group OR = 1.52 (95% CI 0.94, 2.46) but this result was not statistically significant. Patients receiving placebo were four times more likely to discontinue treatment because of lack of efficacy than patients receiving auranofin OR=0.29 (95% CI: 0.19, 0.43).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Auranofin appears to have a small clinically and statistically significant benefit on the disease activity of patients with RA. The beneficial effects appear to be modest compared to drugs such as methotrexate or parenteral gold. Its effects on long term health status and radiological progression are not clear at this time.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>A number of disease-modifying antirheumatic drugs (DMARDs) can be used to treat patients with rheumatoid arthritis (RA). These drugs have a more profound effect than anti-inflammatory agents. Although most patients with RA will have increased articular damage over the years, DMARDs are believed to limit or retard this disease progression, compared to anti-inflammatory drugs which only have a symptomatic effect alleviating the pain and stiffness. Auranofin is an oral gold compound which has been used for the treatment of RA since the early 1980's. Auranofin was developed as an alternative to parenteral gold compounds. Parenteral gold is an effective treatment for RA but its use is limited by its toxicity which can be serious. Furthermore, parenteral gold salts are administered weekly by intramuscular injection, which is less convenient for patients than oral administration. Auranofin is more frequently used in some areas of the world such as some European countries compared to Canada or the United States. A number of studies have evaluated auranofin in comparison to placebo, but the results have not been consistent. Some of the variation in use may relate to the differences in the reported magnitude of clinical benefits across trials. </P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this study was to evaluate the short-term efficacy of auranofin in comparison to placebo for the treatment of RA.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomized controlled trials (RCTs) and controlled clinical trials (CCT), with a minimum duration of 6 months.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with a diagnosis of RA (as stated in the publication).<BR/>Age &gt;16 years old.<BR/>Patients receiving no DMARDs other than auranofin.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Intervention group: auranofin, minimum dosage 6 mg/day, oral administration</P>
<P>Control group: placebo</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Outcome endpoints included measures of efficacy and toxicity.</P>
<P>1. Efficacy<BR/>All the outcome measures in OMERACT (<LINK REF="REF-OMERACT-1993" TYPE="REFERENCE">OMERACT 1993</LINK>) and the American College of Rheumatology (ACR) (<LINK REF="REF-Felson-1995" TYPE="REFERENCE">Felson 1995</LINK>) were included for potential analysis, although only some were consistently reported across trials.</P>
<P>OMERACT measures for efficacy include:<BR/>a) Number of tender joints <BR/>b) Number of swollen joints <BR/>c) Pain<BR/>d) Physician global assessment<BR/>e) Patient global assessment<BR/>f) Functional status<BR/>g) Acute phase reactants (e.g. erythrocyte sedimentation rate, ESR)<BR/>h) Radiological damage</P>
<P>2. Withdrawals and dropouts - these were analyzed as:</P>
<P>a) Total number of withdrawals and dropouts<BR/>b) Number of withdrawals from lack of efficacy<BR/>c) Number of withdrawals due to concurrent illness<BR/>d) Number of withdrawals due to adverse reactions<BR/>e) Number of withdrawals due to system-specific adverse reactions (e.g. gastrointestinal, renal, etc.) </P>
<P>3. Adverse reactions (ADRs) not causing withdrawal were analysed by system:<BR/>a) Gastrointestinal - all signs and symptoms plus diarrhea only<BR/>b) Mucosal / cutaneous <BR/>c) Renal <BR/>d) Liver<BR/>e) Hematological <BR/>f) Neurological (headache, dizziness, tingling)<BR/>g) Miscellaneous adverse reactions</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>1. Electronic searches<BR/>A comprehensive MEDLINE search was performed using the strategy developed by Dickersin et al (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) from 1966 to December 1998.<BR/>EMBASE was searched from 1988 to December 1998, with a strategy similar to the one used for MEDLINE</P>
<P>2. Hand searches<BR/>Reference lists of all the trials selected through the electronic search were manually searched to identify additional trials.</P>
<P>3. The Controlled Clinical Trials Register (CCTR) was also searched.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Data extracted from the publications included study characteristics and outcome measures of efficacy and toxicity. Data was extracted by one reviewer and cross checked by a second. </P>
<P>1. Efficacy</P>
<P>The results on efficacy were analysed for the 6-month endpoint. Although some trials had longer duration, this endpoint was chosen because it was reported in most of the trials and was thought to be the minimum required time to adequately assess the efficacy of auranofin. </P>
<P>Nine trials were included in the review. Each study reported at least one OMERACT outcome measure and could be included in the meta-analysis. The most consistently reported measures were joint and pain scores. Three different measures of function were reported by at least one trial. The three functional measures were not pooled, and were analyzed separately in a subgroup analysis. </P>
<P>The analysis compares end of trial results. When the standard deviation (SD) was not reported, we used either the baseline SD or imputed a SD from the weighted average coefficient of variation (CV) calculated from the other trials. (CV = SD/mean) If trials reported medians and ranges, the median was entered as the mean, the range was divided by 3 to estimate the SD. (Interquartile ranges were divided by 2 to estimate a SD.) Change from baseline scores were converted to end of trial results when baseline values were available. When imputing a SD we elected to be as conservative as possible. We thought these procedures would introduce less bias than excluding the trial altogether. </P>
<P>End-of-trial results were pooled as standardized weighted mean differences for joint scores, and global assessments. This was necessary because of the variation in the outcome measures included in each study (e.g. number of tender joints, tender joint index). All trials that reported pain scores had used a VAS scale therefore pain results were pooled using a weighted mean difference. ESR results were also pooled using a weighted mean difference.</P>
<P>Trial results were entered in RevMan using the same direction to enable the pooling of results where the lowest value was improvement and the highest value was worsening. Negative values in standardized weighted means indicate a benefit of the active drug over placebo. </P>
<P>2. Withdrawals and dropouts</P>
<P>Adverse reactions (ADRs) were generally reported as overall results at the end of the trial. We therefore pooled withdrawals and dropouts at the end of the study, although in some cases follow-ups exceeded 6 months. Toxicity was analysed using a pooled odds ratio for total withdrawals from adverse reactions, and withdrawals for system-specific side-effects. </P>
<P>The heterogeneity of the trials for each pooled analysis was estimated using a chi-square test. Fixed effects models were used throughout. Random effects models were only used for outcomes showing statistically significant heterogeneity.</P>
<P>All studies reported global reasons for withdrawal or dropout but not all reported ADRs by system. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Nine parallel design RCTs met the criteria for inclusion. Three trials were conducted in North America, five in the UK and Europe, one in New Zealand, all between the years 1982 and 1997. </P>
<P>All trials included patients with active RA. <LINK REF="STD-Glennas-1997" TYPE="STUDY">Glennas 1997</LINK> accepted only those with elderly onset (i.e. &gt; 60 yr), while <LINK REF="STD-Davies-1982" TYPE="STUDY">Davies 1982</LINK> and <LINK REF="STD-Johnsen--1989" TYPE="STUDY">Johnsen 1989</LINK> accepted only those with early disease (i.e. &lt; 3 and 2 years respectively). </P>
<P>Auranofin was administered orally at a dose of 6 mg/day in all trials. The duration of trials ranged from 21 weeks to 2 years.</P>
<P>No single measure was reported by all nine trials. Tender joint indices, pain scores and ESR were adequately reported to allow pooling in seven studies, swollen joints in six, patient global assessment in four and physician global in three. One of the studies (<LINK REF="STD-Lewis-1984" TYPE="STUDY">Lewis 1984</LINK>) reported the results for a disease activity index which combined several measures, and p values for each single measure; only ESR could be pooled with results from other trials. Four studies included one or more functional scales. <LINK REF="STD-Bombardier-1986" TYPE="STUDY">Bombardier 1986</LINK> included a number of functional measures and quality of life instruments. The purpose of this study was to examine changes in overall health with a number of instruments. We chose three of these measures for comparative purposes in this review including the Health Assessment Questionnaire, Keitel Assessment and 15m walk time. We felt that of all of the measures reported these were the most commonly used in patients with RA. The other two studies reported changes in Health Assessment Questionnaire and walk time. An additional trial (<LINK REF="STD-Ward-1983" TYPE="STUDY">Ward 1983</LINK>) reported functional class. This is a 4-point scale which is not considered to be as discriminative as the other measures in this study and was not included in the review.</P>
<P>Three studies reported radiological progression (<LINK REF="STD-Prouse-1982" TYPE="STUDY">Prouse 1982</LINK>, <LINK REF="STD-Johnsen--1989" TYPE="STUDY">Johnsen 1989</LINK>, <LINK REF="STD-Glennas-1997" TYPE="STUDY">Glennas 1997</LINK>). The results were reported in a similar fashion and were not pooled, but are summarized in the text of the review. Another two trials (Ward 1983; Wenger 1983) reported that they performed x-rays but the results were not included in any of the publications identified for this review. Three studies (<LINK REF="STD-Davies-1982" TYPE="STUDY">Davies 1982</LINK>, <LINK REF="STD-Lewis-1984" TYPE="STUDY">Lewis 1984</LINK>, <LINK REF="STD-Ward-1983" TYPE="STUDY">Ward 1983</LINK>) included a third arm involving gold sodium thiomalate (GSTM). The results related to parenteral gold are not included in the present review. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The methodological quality of the studies was assessed by two of the investigators using a quality scale validated and published by <LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>. This scale includes an assessment of randomization, double-blinding procedures and description of withdrawals. The possible range of scores is 0 (worst) to 5 (best). Two studies had a score of 5, five a score of 4, and two a score of 3. (See table of included studies). Concealment of allocation was considered adequate in four studies, and unclear in five. Disagreements were resolved by consensus.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>A total of 539 people received auranofin while 510 received placebo.</P>
<P>Efficacy </P>
<P>Data for all the outcome measures was not reported by all the studies. The number of trials included for each analysis ranged from one to seven.<BR/>Statistically significant improvements favouring auranofin were noted for tender joint scores, pain scores, global patient and physician assessments and ESR. For tender joint scores the SMD was -0.39 (95% CI -0.54, -0.25), and for patient assessments the SMD was -0.20 (95% CI -0.38, -0.03) . There was demonstrated heterogeneity in the pooled result for physician assessments, therefore this result is reported using random effects. The SMD for physician global assessment was -0.38 (95% CI -0.73, -0.02). The WMD between auranofin and placebo scores for pain was -4.68 (95% CI -6.59, -2.77) and for ESR values was -9.85 (95% CI -16.46, -3.25). The pooled ERS results also showed heterogeneity so random effects estimates are reported. The heterogeneity was due to the Johnsen study which included only patients with RA of less than two years duration. No significant differences were observed between auranofin and placebo groups in swollen joint scores; these trials were also heterogeneous, but no major differences were observed between fixed and random effects. The heterogeneity was due to the results reported in <LINK REF="STD-Glennas-1997" TYPE="STUDY">Glennas 1997</LINK>. Removing this trial corrected the heterogeneity but did not change substantially the results which remained insignificant. </P>
<P>No significant differences were observed in the measures that examined function (Health Assessment Questionnaire, Keitel Assessment or 50 ft. walk times) or in global assessment measures by physician or patients. </P>
<P>
<LINK REF="STD-Lewis-1984" TYPE="STUDY">Lewis 1984</LINK> reported a disease activity index which combined six clinical variables (duration of morning stiffness, pain, grip strength, articular index, hemoglobin and ESR). Only p values were reported for most single measures and therefore only the ESR results could be pooled with those from other trials. At 24 weeks, the auranofin group showed significant improvement in pain, disease activity index and ESR.</P>
<P>Withdrawals from lack of efficacy were less frequent in the auranofin group (OR: 0.31, 95% CI: 0.21-0.44).</P>
<P>Three studies reported radiological outcomes (<LINK REF="STD-Prouse-1982" TYPE="STUDY">Prouse 1982</LINK>, <LINK REF="STD-Johnsen--1989" TYPE="STUDY">Johnsen 1989</LINK>, <LINK REF="STD-Glennas-1997" TYPE="STUDY">Glennas 1997</LINK>). <LINK REF="STD-Prouse-1982" TYPE="STUDY">Prouse 1982</LINK> stated that at three months, xray changes generally showed progression in those not responding clinically to gold therapy and amongst placebo group. Changes in those responding to therapy was variable. At 12 months only one patient on active therapy was thought to have progression. The actual aggregated data were not reported so no statistical inferences could be made. The results from <LINK REF="STD-Johnsen--1989" TYPE="STUDY">Johnsen 1989</LINK> were reported at two years (<LINK REF="STD-Borg-1991" TYPE="STUDY">Borg 1991</LINK>) and showed that the placebo group had significantly more progression than the auranofin group measured by Larsen scores. These results were based on an intent to treat analysis. In <LINK REF="STD-Glennas-1997" TYPE="STUDY">Glennas 1997</LINK> results from 49 of 65 (75%) of patients showed no statistically significant intergroup differences or changes in the Larsen-Dale index over 24 months. </P>
<P>Two studies had a longer duration, two years. One of them (Johnsen 1989) reported 2-year outcomes in a subsequent publication (Borg 1991): 53% (35) of the patients on auranofin and 37% (24) on placebo remained on trial drugs for the two years. There were improved effects noted especially in ESR, Ritchie index and number of swollen joints in those who remained on auranofin. A larger proportion of these patients could reduce (31 vs 17%) or stop (23 vs 4%) treatment with NSAIDS than those on placebo. Those on auranofin required fewer local steroid injections than those on placebo (37 vs 58%).<BR/>In the other study (Glennas 1997) 55% patients on auranofin completed the two year trial compared to 18% receiving placebo. </P>
<P>Toxicity</P>
<P>Analysis of withdrawals and dropouts was available for all trials. Overall, patients on auranofin were significantly less likely to withdraw than those receiving placebo: OR = 0.62 (95%CI: 0.46, 0.83). Patients on auranofin were significantly less likely to withdraw from lack of efficacy OR = 0.31 (95%CI: 0.21, 0.44) but were 1.5 times more likely to withdraw due to adverse reactions OR = 1.52 (95% CI 0.94, 2.46) however this difference was not statistically significant.</P>
<P>Patients taking auranofin demonstrated significantly higher withdrawal rates in only two system specific areas: 1) gastrointestinal symptoms in general OR = 2.98 (95% CI 1.36, 6.52), particularly diarrhea OR = 3.02 (95% CI 1.29, 7.06) and 2) mucosal or cutaneous reactions OR = 1.56 (95% CI 0.75, 3.23). Overall, 3.7%, and 3.5% of patients taking auranofin experienced gastrointestinal symptoms or muco/cutaneous reactions severe enough to cause withdrawal or change in therapy. This same trend was observed in pooled OR results reporting frequency of ADR (with or without withdrawal). Withdrawals due to hematological or renal effects were rare (1% each). Glennas and Bombardier (1986) reported ADRs as total number of events of a specific ADR reported per group rather than events per person thus are not included in the pooled OR with the other trials. Glennas reported a rate of 8.5 ADR events per person in the auranofin group vs 7.6 events per person in the placebo group; 142 gastrointestinal ADRs (51 were diarrhea) were reported in 31 persons taking auranofin compared to 152 GI complaints (85 were diarrhea) in 34 persons taking placebo. Muco-cutaneous, renal and liver ADRs were more frequent in the placebo group, and headaches and general complaints in the auranofin group. Over the course of the study 10 % vs 41% withdrew due to ADRs respectively. Bombardier reported a rate of 1.92 ADR events per person in the auranofin group vs 1.02 events per person in the placebo group. ADRs numbering 174 related to gastrointestinal events (93 were diarrhea) were reported in 157 persons taking auranofin compared to 82 complaints (29 were diarrhea) in 152 persons taking placebo. Most frequent gastrointestinal complaint was loose stools or diarrhea which generally occurred early and often resolved itself while cutaneous reactions occurred throughout. Muco-cutaneous ADRs were more common in the auranofin group, 74 events in 157 auranofin patients vs 59 events in 152 patients. All ADRs were reversible. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Gold salts were the first DMARD used for the treatment of RA. The most commonly used compounds are sodium aurothiomalate and aurothioglucose. These salts are administered weekly as intramuscular injections. The efficacy of parenteral gold salts has been well established (<LINK REF="REF-Clark-1999" TYPE="REFERENCE">Clark 1999</LINK>). However, its toxicity is frequent and can be serious. Mucocutaneous manifestations, in particular rash are very common. Hematological effects include leucopenia, thrombocytopenia, and in rare cases aplatic anemia. Renal effects such as proteinuria are also frequent and result in discontinuation of the drug. These drawbacks led to the search for gold compounds which could be administered orally, and had lower toxicity profiles. Auranofin was developed in the 1970's and the reports of the first RCTs were published in the 1980's. Despite the initial enthusiasm subsequent studies showed that auranofin was not as potent as parenteral gold (Felson 1990, <LINK REF="REF-Berkey-1996" TYPE="REFERENCE">Berkey 1996</LINK>) although it had a safer toxicity profile.</P>
<P>The objective of this study was to conduct a systematic review of placebo-controlled trials of auranofin for the treatment of RA. We have conducted a number of systematic reviews for other DMARDS using the same methods which allow us to compare the efficacy of a DMARD in relation to other drugs. The results of the review show that auranofin is efficacious in reducing disease activity in patients with RA over a 6 month period. Statistically significant results favouring auranofin were observed for number of tender joints, pain scores, physician and patient global assessments and ESR. The magnitude of the differences between placebo and auranofin was nevertheless small. The effect size for tender joints was 0.39, the difference in pain 5mm on a 0 to 100mm scale, and the difference in ESR 10mm/hr. No significant differences were observed for functional status These results suggest that auranofin has a small beneficial effect on the disease activity of patients with RA. When the efficacy of auranofin is compared to the results obtained in meta-analyses of other DMARDs, auranofin appears to be less potent than some of the other drugs including parenteral gold, methotrexate, sulfasalazine and cyclosporine (Felson 1990, <LINK REF="REF-Suarez_x002d_Almazor-1999a" TYPE="REFERENCE">Suarez-Almazor 1999a</LINK>, <LINK REF="REF-Suarez_x002d_Almazor-1999b" TYPE="REFERENCE">Suarez-Almazor 1999b</LINK>, <LINK REF="REF-Suarez_x002d_Almazor-1999c" TYPE="REFERENCE">Suarez-Almazor 1999c</LINK>, Wells 1999). However, the confidence limits of the estimated effects overlap for most measures so the differences cannot be considered to be statistically significant . For these other DMARDS, the effect sizes in the meta-analyses of placebo-controlled trials were approximately 0.5 to 0.6. For auranofin the effect sizes ranged between 0.20 and 0.40. Effect sizes of 0.30 and higher can be considered clinically significant (<LINK REF="REF-Kazis-1989" TYPE="REFERENCE">Kazis 1989</LINK>). The efficacy of auranofin appears to be very comparable to that of antimalarials, with similar effect sizes for both drugs when compared with placebo (Suarez-Almazor 1999d). However, in the systematic review of antimalarials, the improvement in swollen joints was statistically significant, but no differences were observed for auranofin in the current review. </P>
<P>The effect of auranofin on the radiological progression of RA remains inconclusive. Unfortunately, some of the trials which measured radiological damage did not report the results. The two trials reporting quantitative results had conflicting findings with one study finding a significant difference (<LINK REF="STD-Johnsen--1989" TYPE="STUDY">Johnsen 1989</LINK>) but not the other (<LINK REF="STD-Glennas-1997" TYPE="STUDY">Glennas 1997</LINK>). </P>
<P>No serious adverse reactions occurred with auranofin. Although patients receiving the drug were 1.5 times more likely to discontinue treatment because of toxicity, but the differences were not statistically significant. Most of the toxicity withdrawals were related to loose stools or diarrhoea and mucocutaneous events. The toxicity observed with auranofin was less frequent and serious than the findings reported with parenteral salts in previous studies were leucopenia and proteinuria are common events. Other DMARDS which may be more effective than auranofin such as methotrexate or cyclosporin have the potential for more serious effects than auranofin. Antimalarials also have a low toxicity profile in the short term, but have a small but definite risk of retinopathy with longer treatments. A meta-analysis by Felson which included placebo-controlled as well as drug-to-drug comparisons concluded that auranofin was one of the least toxic DMARDS as measured by the number of discontinuations. When choosing one drug over another risk-benefit ratios have to be considered in relation to the severity of the disease, and patient preferences.</P>
<P>In this review, some of the studies only included patients with early disease. Because auranofin may be somewhat weaker than other DMARDS its most appropriate use may be for those patients with early, mild disease who are more likely to respond to any therapy.</P>
<P>The role of auranofin in combination with other drugs has not been adequately assessed so far. Combination therapy with two or more DMARDS is increasingly being used to treat patients with RA, most frequently those who fail treatment with a single drug.. One study compared methotrexate, auranofin and the combination of both and found no clear advantage in using the combined therapies (Williams 1992). </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Auranofin appears to be efficacious in the short-term treatment of patients with RA (6 months), and has a small but clinically and statistically significant benefit on the disease activity of these patients. Its effects on overall health status and radiological progression are not clear at this time, but would appear to be modest. Auranofin may be most appropriate for those patients with early and mild disease who are more likely to respond to less potent (and less toxic) therapies.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The role of auranofin in combination with other DMARDS deserves further study. <BR/>Many of the studies did not report (or reported inadequately) outcomes of interest which made it impossible to pool results for all measures across trials. This reinforces the need to use systematic methods or guidelines when designing, conducting and publishing clinical trials (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>All the authors participated in the development of the protocol and searches. CH Spooner and E Belseck appraised the publications and extracted the data from the trials.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bombardier-1986" NAME="Bombardier 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL</AU>
<TI>Auranfin therapy and quality of life in patients with rheumatoid arthritis</TI>
<SO>Am J Med</SO>
<YR>1986</YR>
<VL>81</VL>
<PG>565-578</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Thompson MS, Read JL, Hutchings HC, Paterson M, Harris ED Jr. The cost effectiveness of auranofin: Results of a randomised clinical trial. J Rheumatol 1988:15:35-42.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson MS, Read JL, Hutchings HC, Paterson M, Harris ED Jr</AU>
<TI>The cost effectiveness of auranofin: Results of a randomised clinical trial</TI>
<PG>35-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1982" NAME="Davies 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Davies J, Bacon PA, Hall ND, Ring EFJ. Placebo-controlled comparison of auranofin with myocrisin in patients with rheumatoid arthritis. In: Capell HA, Cole DS, Manghani KK &amp;amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp;amp; French International Symposium . Exerpta Medica, Netherlands (Amsterdam) 1983;194-200.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies J, Bacon PA, Hall ND, Ring EFJ</AU>
<TI>Placebo-controlled comparison of auranofin with myocrisin in patients with rheumatoid arthritis. In: Capell HA, Cole DS, Manghani KK &amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium</TI>
<SO>Exerpta Medica, Netherlands (Amsterdam)</SO>
<YR>1983</YR>
<PG>Capell HA, Cole DS, Manghani KK &amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium . Exerpta Medica, Netherlands (Amsterdam) 1983;194-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies J, Bacon PA, Hall ND, Ring EFJ</AU>
<TI>Placebo-controlled comparison of oral gold with injectable gold in early rheumatoid arthritis</TI>
<SO>Clin Rheumatol</SO>
<YR>1984</YR>
<VL>3</VL>
<PG>553-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glennas-1997" NAME="Glennas 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Glennas A, Kvien TK, Andrup O, Clarke-Jenssen, Karstensen B, Brodin U. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br J Rheumatol 1997:36:870-877.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glennas A, Kvien TK, Andrup O, Clarke-Jenssen, Karstensen B, Brodin U</AU>
<TI>Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1997</YR>
<VL>36</VL>
<NO>8</NO>
<PG>870-877</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnsen--1989" NAME="Johnsen  1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borg G, Allander E, Lund B, Berg E, Brodin U, Pettersson H, Trang L</AU>
<TI>Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind, placebo controlled study</TI>
<SO>J Rheumatol</SO>
<YR>1988</YR>
<VL>15</VL>
<PG>1747-1754</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnsen V, Borg G, Trang LE, Berg E, Brodin U</AU>
<TI>Auranofin (SK&amp;F) in early rheumatoid arthritis: Results from a 24-month double blind, placebo-controlled trial</TI>
<SO>Scand J Rheumatol</SO>
<YR>1989</YR>
<VL>18</VL>
<PG>251-260</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1984" NAME="Lewis 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Lewis D, Capell HA. Is auranofin preferable to gold sodium thiomalate in the management of rheumatoid arthritis. In: Capell HA, Cole DS, Manghani KK &amp;amp; Morris RW (eds). Auranofin, Proceedings of a Smith Kline &amp;amp; French International Symposium. Exerpta Medica, Netherlands (Amsterdam) 1983;147-155.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis D, Capell HA</AU>
<TI>Is auranofin preferable to gold sodium thiomalate in the management of rheumatoid arthritis. In: Capell HA, Cole DS, Manghani KK &amp; Morris RW (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium</TI>
<SO>Exerpta Medica, Netherlands (Amsterdam)</SO>
<YR>1983</YR>
<PG>Capell HA, Cole DS, Manghani KK &amp; Morris RW (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium. Exerpta Medica, Netherlands (Amsterdam) 1983;147-155</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis D, Capell HA</AU>
<TI>Oral gold: A comparison with placebo and intramuscular sodium aurothiomalate</TI>
<SO>Clin Rheumatol</SO>
<YR>1984</YR>
<VL>Supp 1</VL>
<PG>83-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palmer-1982" NAME="Palmer 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Palmer DG, Highton J, MacKinnon M, Myers DB, Sharma R. A double-blind parallel trial of auranofin and placebo in rheumatoid arthritis with evidence for compatibility with certain non-steroidal anti-inflammatory drugs. In: Capell HA, Cole DS, Manghani KK &amp;amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp;amp; French International Symposium. Exerpta Medica, Netherlands (Amsterdam) 1983;313-324.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmer DG, Highton J, MacKinnon M, Myers DB, Sharma R</AU>
<TI>A double-blind parallel trial of auranofin and placebo in rheumatoid arthritis with evidence for compatibility with certain non-steroidal anti-inflammatory drugs. In: Capell HA, Cole DS, Manghani KK &amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium</TI>
<SO>Exerpta Medica, Netherlands (Amsterdam)</SO>
<YR>1983</YR>
<PG>Capell HA, Cole DS, Manghani KK &amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium. Exerpta Medica, Netherlands (Amsterdam) 1983;313-324</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prouse-1982" NAME="Prouse 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Prouse PJ, Gumpel JM. Placebo-controlled comparison of auranofin with gold sodium thiomalate. In: Capell HA, Cole DS, Manghani KK &amp;amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp;amp; French International Symposium. Exerpta Medica, Netherlands (Amsterdam) 1983;303-312&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prouse PJ, Gumpel JM</AU>
<TI>Placebo-controlled comparison of auranofin with gold sodium thiomalate. In: Capell HA, Cole DS, Manghani KK &amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium</TI>
<SO>Exerpta Medica, Netherlands (Amsterdam)</SO>
<YR>1983</YR>
<PG>Capell HA, Cole DS, Manghani KK &amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium. Exerpta Medica, Netherlands (Amsterdam) 1983;303-312</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-1983" NAME="Ward 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward JR, Williams HJ, Boyce E, Egger MJ, Reading JC, Samuelson CO</AU>
<TI>Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis</TI>
<SO>Am J Med</SO>
<YR>1983</YR>
<VL>133-137</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward JR, Williams HJ, Egger MJ, Reading JC, Boyce E, Altz-Smith M, et al</AU>
<TI>Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: A controlled clinical trial</TI>
<SO>Arthritis Rheum</SO>
<YR>1983</YR>
<VL>26</VL>
<NO>11</NO>
<PG>1303-1315</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ward JR, Williams HJ, Egger MJ, Reading JC, Boyce E, Samuelson Jr CO, et al. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis: Response by treatment duration. In: Capell HA, Cole DS, Manghani KK &amp;amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp;amp; French International Symposium ..Exerpta Medica, Netherlands (Amsterdam). 1983;115-132.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward JR, Williams HJ, Egger MJ, Reading JC, Boyce E, Samuelson Jr CO, et al</AU>
<TI>Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis: Response by treatment duration. In: Capell HA, Cole DS, Manghani KK &amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium ..Exerpta Medica, Netherlands (Amsterdam)</TI>
<YR>1983</YR>
<PG>Capell HA, Cole DS, Manghani KK &amp; Morris RW. (eds). Auranofin, Proceedings of a Smith Kline &amp; French International Symposium ..Exerpta Medica, Netherlands (Amsterdam). 1983;115-132</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams HJ &amp; Ward JR</AU>
<TI>Comparison of oral and parenteral gold therapy and placebo in the treatment of rheumatoid arthritis</TI>
<SO>Scand J of Rheum</SO>
<YR>1983</YR>
<VL>Supp</VL>
<NO>51</NO>
<PG>92-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wenger-1983" NAME="Wenger 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gofton JP, O'Brien WM, Hurley JN, Scheffler BJ</AU>
<TI>Radiographic evaluation of erosion in rheumatoid arthritis: Double blind study of auranofin vs placebo</TI>
<SO>J Rheumatol</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>6</NO>
<PG>768-771</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz WA, Alexander S, Bland JH, Blechman W, Bluhm GB, Bonebrake RA, Falbo A, et al</AU>
<TI>The efficacy of Auranofin compared to placebo in rheumatoid arthritis</TI>
<SO>J of Rheumatol Supplement</SO>
<YR>1982</YR>
<VL>8</VL>
<PG>173-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Wenger ME, Alexander S, Bland JH, Blechman W, Auranofin vs placebo in the treatment of rheumatoid arthritis. Am J of Med1983;123-127.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wenger ME, Alexander S, Bland JH, Blechman W, Auranofin vs placebo in the treatment of rheumatoid arthritis</AU>
<SO>Am J of Med</SO>
<YR>1983</YR>
<VL>123-127</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldassare-1985" NAME="Baldassare 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>* Baldassare AR, Weiss TD, Arthur RE, Osborn TG, Moore TL &amp; Zuckner J</AU>
<TI>Auranofin in the treatment of rheumatoid arthritis: A two year study</TI>
<SO>Missouri Medicine</SO>
<YR>1985</YR>
<VL>82</VL>
<NO>11</NO>
<PG>711-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borg-1991" NAME="Borg 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borg G, Allander E, Berg E, Brodin U, From A &amp; Trang L</AU>
<TI>Auranofin treatment in early rheumatoid arthritis may postpone early retirement. Results from a 2-year double blind trial</TI>
<SO>J Rheum</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>7</NO>
<PG>1015-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Champion-1982" NAME="Champion 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Champion DG, Bieri D, Browne CD, Cohen ML, Day RO, Graham GG, Haavisto TM, Sambrook PN &amp; Vallance JB</AU>
<TI>Auranofin in rheumatoid arthritis</TI>
<SO>J Rheum Supplement</SO>
<YR>1982</YR>
<VL>8</VL>
<PG>137-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Champion-1988" NAME="Champion 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Champion DG, Cairns DR, Bieri D, Adena MA, Browne CD, Cohen ML, et al</AU>
<TI>Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis</TI>
<SO>J Rheumatol</SO>
<YR>1988</YR>
<VL>15</VL>
<PG>28-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egsmose-1995" NAME="Egsmose 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U &amp; Trang L</AU>
<TI>Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study</TI>
<SO>J Rheum</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>12</NO>
<PG>2208-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jajic-1990" NAME="Jajic 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jajic I, Jajic Z, Kos-Golja M</AU>
<TI>Klinicka djelotvornost i podnosljivost auranofina u lijecenju reumatoidnog artritisa [Clinical efficacy and safety of auranofin in the treatment of rheumatoid arthritis]</TI>
<SO>Rad Med Fak Zagrebu</SO>
<YR>1990</YR>
<VL>31</VL>
<NO>5</NO>
<PG>299-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundberg-1988" NAME="Lundberg 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundberg MS, Cannon GW, Ward JR</AU>
<TI>Peripheral lymphocyte depletion in gold sodium thiomalate-treated rheumatoid arthritis patients</TI>
<SO>Arthritis Rheum</SO>
<YR>1988</YR>
<VL>31</VL>
<NO>7</NO>
<PG>909-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S et al</AU>
<TI>Improving the quality of randomized controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berkey-1996" NAME="Berkey 1996" TYPE="JOURNAL_ARTICLE">
<AU>Berkey CS, Anderson JJ, Hoaglin DC</AU>
<TI>Multiple outcome meta-analysis of clinical trials</TI>
<SO>Stat Med</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>537-557</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-1999" NAME="Clark 1999" NOTES="&lt;p&gt;Clark P, Tugwell P, Bennet K, et al. Meta-analysis of injectable gold in rheumatoid arthritis. In: Tugwell P, Brooks P, Wells G, de Bie R, Bosi-Ferraz M, Gillespie W, eds. Musculoskeletal module of The Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 3, 1998. Oxford: Update Software. Search date 1997; primary sources Medline 1966 to July 1997 and hand search of reference lists and bibliographies in selected textbooks.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Clark P, Tugwell P, Bennet K, et al</AU>
<TI>Meta-analysis of injectable gold in rheumatoid arthritis.</TI>
<SO>In: Tugwell P, Brooks P, Wells G, de Bie R, Bosi-Ferraz M, Gillespie W, eds. Musculoskeletal module of The Cochrane Database of Systematic Reviews. In: The Cochrane Library, Oxford: Update Software</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K</AU>
<TI>, Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1993" NAME="Felson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M et al</AU>
<TI>The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials</TI>
<SO>Arthritis Rheum</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>729-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1995" NAME="Felson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M et al</AU>
<TI>American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis</TI>
<SO>Arthritis Rheum</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>727-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carrol D, et al</AU>
<TI>Assessing the quality of reports of randomized trials: is blinding necessary?</TI>
<SO>Control Clin Trial</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kazis-1989" NAME="Kazis 1989" TYPE="JOURNAL_ARTICLE">
<AU>Kazis LEE, Anderson JJ, Meenan RF</AU>
<TI>Effect sizes for interpreting changes in health status</TI>
<SO>Medical Care</SO>
<YR>1989</YR>
<VL>27</VL>
<NO>S3</NO>
<PG>S178-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OMERACT-1993" NAME="OMERACT 1993" TYPE="JOURNAL_ARTICLE">
<AU>OMERACT</AU>
<TI>Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials</TI>
<SO>J Rheumatol</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>526-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suarez_x002d_Almazor-1999a" NAME="Suarez-Almazor 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P.</AU>
<TI>Rheumatoid arthritis (RA): methotrexate versus placebo.</TI>
<SO>In: Tugwell P, Brooks P, Wells G, de Bie R, Bosi-Ferraz M, Gillespie W, eds. Musculoskeletal module of The Cochrane Database of Systematic Reviews. In: The Cochrane Library, Oxford: Update Software</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suarez_x002d_Almazor-1999b" NAME="Suarez-Almazor 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P.</AU>
<TI>Rheumatoid arthritis (RA): sulfasalazine vs. placebo.</TI>
<SO>In: Tugwell P, Brooks P, Wells G, de Bie R, Bosi-Ferraz M, Gillespie W, eds. Musculoskeletal module of The Cochrane Database of Systematic Reviews. In: The Cochrane Library, Oxford: Update Software</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suarez_x002d_Almazor-1999c" NAME="Suarez-Almazor 1999c" TYPE="JOURNAL_ARTICLE">
<AU>Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P.</AU>
<TI>Rheumatoid arthritis (RA): antimalarials vs. placebo</TI>
<SO>In: Tugwell P, Brooks P, Wells G, de Bie R, Bosi-Ferraz M, Gillespie W, eds. Musculoskeletal module of The Cochrane Database of Systematic Reviews. In: The Cochrane Library, Oxford: Update Software.</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bombardier-1986">
<CHAR_METHODS>
<P>Allocation: randomized in blocks of 8 stratified for steroid use. <BR/>Blinding: double blind<BR/>Design: parallel study<BR/>Sample size at entry: 311 <BR/>Analysis: completers, 97% follow-up; auranofin 154; placebo 149</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada &amp; US, Multicentre tial (K=14)<BR/>Patients with active RA <BR/>Age: mean 50.5 yr (SD 11.08) <BR/>Duration of disease: mean 8.05 yr (SD 8.0)<BR/>Females: 73%<BR/>RF: 74% <BR/>Concomitant use of steroids: oral 23.5% <BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: not in previous 6 mo.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Auranofin 6 (could increase to 9) mg /day vs identical placebo<BR/>Treatment duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joint count<BR/>Swollen joint count<BR/>Pain: 3 scales. Included only 10 cm pain line, 10=severe<BR/>Function: 4 scales. Included 2: Health Assessment Questionnaire (0 to 3, 3=worse) and Keitel function test (0-98, 98=worse)<BR/>Patient assessment: 4 scales. Included only 10 cm line, 10 = perfect<BR/>Physician assessment: 3 scales. Included only 10 cm line, 10 = perfect<BR/>50 ft walk time in seconds (results in text only )<BR/>Quality of life: quality of wellbeing scale (results in text only)<BR/>ESR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Allocation concealment: adequate<BR/>Reported: baseline &amp; SE, mean change scores &amp; SE<BR/>Calculated baseline SD values &amp; imputed them to end-of-trial results <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davies-1982">
<CHAR_METHODS>
<P>Allocation: randomised <BR/>Blinding: double blind <BR/>Design: parallel study<BR/>Sample size at entry: Auranofin 10; GSTM 11, placebo 11<BR/>Analysis: completers 85.7% (auranofin 10, placebo 8)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>Patients with active RA (early, mild disease)<BR/>Age: mean 53.3 yr<BR/>Duration of disease: mean 3.02 yr<BR/>Females: 72%<BR/>RF: not reported<BR/>Concomitant use of steroids or other DMARD: none <BR/>Previous use of DMARDS or steroids: none<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Auranofin 6m g/day, GSTM IM 50 mg/wk or placebo<BR/>Treatment duration: 12 mo, 9 m data reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joints: Ritchie index<BR/>Pain VAS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Allocation concealment: unclear<BR/>Group using GSTM not included in analysis<BR/>Reported: baseline &amp; end of trial values. Imputed 12 mo SD to 9 mo data for Ritchie index<BR/>Withdrawals at six mo. reported <BR/>ADR results reported at 9 months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Glennas-1997">
<CHAR_METHODS>
<P>Allocation: randomized, blocks of 4, stratified for RH and myalgias<BR/>Blinding: double blind <BR/>Design: parallel study<BR/>Sample size at entry 65: auranofin 31; placebo 34<BR/>Analysis: Intention to treat 78.5% follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Norway<BR/>Patients with active RA: onset age &gt;60 yr. 4 pts in auranofin gr had oligoarthritis with PMR or myalgias.<BR/>Age: median 71 y (SD 8)<BR/>Duration of disease: median auranofin 16 wk (SD 172); placebo 25wk (SD 259)<BR/>Females: 68%<BR/>RF: auranofin 32%, placebo 35%<BR/>Concomitant use of steroids: oral &amp; intra-articular allowed<BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: 16%, no previous gold Tx</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Auranofin 6 mg/day vs identical placebo<BR/>Treatment duration: 2 yrs<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Swollen joints<BR/>Pain: 100mm VAS<BR/>Function: HAQ<BR/>Xray: baseline vs 2 yr: Larsen-Dale (range 0-150)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 5<BR/>Allocation concealment: adequate<BR/>Reported: baseline medians &amp; ranges. 6 mo results &amp; SDs estimated from box &amp; whisker plots. Median = mean; SD = IQ range/2<BR/>Reasons for withdrawal reported at 24 months<BR/>ADRs reported by # of events/group not per person, therefore not included in ORs for ADRs not requiring withdrawal. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Johnsen--1989">
<CHAR_METHODS>
<P>Allocation: randomized (blocks of 4 within each centre, size of block unknown to investigator) <BR/>Blinding: double blind<BR/>Design: parallel study<BR/>Sample size at entry: 132. auranofin 67; placebo 65 <BR/>Analysis: Completers, 81.8% follow-up <BR/>(auranofin 57, placebo 51)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: 5 Nordic countries (K=11)<BR/>Patients with active RA (early disease, &lt; 2 yr)<BR/>Age: mean 57 yr. (SD 9.5)<BR/>Duration of disease: mean 11 mo. (SD 6)<BR/>Females: 63%<BR/>RF: 66% <BR/>Concomitant use of steroids: Intra-articular steroids allowed<BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: no gold salts, penicillamine, or levamisole. No antimalarials in past 1 mo.<BR/>All patients on NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Auranofin 6 mg/day vs indentical placebo<BR/>Treatment duration: 24 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joints: Ritchie index<BR/>Swollen joint count<BR/>Pain: 100 mm VAS, 100=worst possible pain<BR/>Function: Stanford Health Assessment Questionnaire &amp; Keitel function test<BR/>Patient assessment: 100 mm VAS, 100=perfect health<BR/>Physician assessment: 100 mm VAS, 100=worst possible deterioration<BR/>ESR<BR/>X-ray: Larsen index, 32 joints, 6 point scale, 5=mutilating changes<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Johnsen 1989 reports 3, 6, 12 &amp; 18 mo results from Borg et al 1988 2 yr. trial. <BR/>Quality score: 4<BR/>Allocation concealment: unclear<BR/>Report: baseline medians with 1st-3rd quartiles. Results reported as % change from baseline median values and quartiles. End of trial results calculated. Medians were imputed as means. End of trial SD = baseline (1st - 3rd quartile)/2 <BR/>6 mo.withdrawal data estimated from graphs <BR/>ADR data reported at 24 months only. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lewis-1984">
<CHAR_METHODS>
<P>Allocation: randomized <BR/>Blinding: double blind for tablet therapy but not injections. Blind assessments. <BR/>Design: parallel study, 3 groups<BR/>Sample size at entry 90: Auranofin 30; placebo 30, GSTM 30.<BR/>Analysis: completers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>Patients with active RA<BR/>Age: median 52.17 yrs (sd 16.7)<BR/>Duration of disease: median 5 yrs (sd 13.00)<BR/>Females: 69%<BR/>RF: 88.9%<BR/>Concomitant use of steriods: none<BR/>Concomitant use of DMARDS: none<BR/>Previous of DMARDS: not in past 6 mo.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Auranofin 6mg/day or matching placebo or GSTM 50 mg IM/wk<BR/>Treatment duration: 6 mos</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ESR<BR/>Disease activity index (combining other measures)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Allocation concealment: unclear<BR/>Except for ESR no OMERACT end of trial results reported <BR/>Six outcome measures were combined to derive a disease activity index.<BR/>Reported ESR changes, imputed baseline SD to end of trial<BR/>Withdrawals and dropouts reported @ 24 wks. ADRs not requiring withdrawal not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Palmer-1982">
<CHAR_METHODS>
<P>Allocation: randomised <BR/>Blinding: double blind<BR/>Design: parallel study<BR/>Sample size at entry 20: auranofin 10; placebo 10<BR/>Analysis: Completers (50% followup)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: New Zealand<BR/>Patients with active RA<BR/>Age: mean 52.25 y<BR/>Disease duration: not reported<BR/>Females: 75%<BR/>RF: not reported<BR/>Concomitant use of steriods: Intra-articular steroids allowed<BR/>Concomitant use of DMARDs: none<BR/>Previous use of DMARDS: none<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Auranofin 6 mg/day vs identical placebo<BR/>Treatment duration: 6 mo.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joints: Ritchie index<BR/>Swollen joints<BR/>Pain<BR/>Patient's assessment score (4 pt scale, 0=nil, 3=excellent)<BR/>Time to walk 5 M<BR/>ESR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Allocation concealment: adequate<BR/>Results estimated from graphs by two reviewers and averaged. No SDs reported. Withdrawals &amp; ADRs reported at 2 yrs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Prouse-1982">
<CHAR_METHODS>
<P>Allocation: randomised<BR/>Blinding: double blind first 6 mo. for auranofin &amp; placebo only<BR/>Design: parallel study, 3 arms (auranofin, GSTM, placebo)<BR/>Sample size at entry 30: auranofin 10; placebo 10, GSTM 10. <BR/>Analysis: Completers 100% follow-up (auranofin 10; placebo 10)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>Patients with active RA<BR/>Age: mean auranofin 57.8 y (SD 11.4)<BR/>Duration of disease: mean auranofin 8.6y (SD 8.1)<BR/>Females: 85%<BR/>RH: not reported<BR/>Concomitant use of steroids: none<BR/>Concomitant use of other DMARDs: none <BR/>Previous use of DMARDs: not reported<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Auranofin 6 mg/day or matching placebo or open GSTM IM 50 mg/wk<BR/>Treatment duration: 6 mo. then reallocated as necessary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Articular index (modified Landsbury)<BR/>Pain<BR/>ESR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 3<BR/>Allocation concealment: unclear<BR/>Data for six mo. abstracted from bar graphs<BR/>SDs imputed from weighted average of CV of other studies. ADRs reported at 12 mo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ward-1983">
<CHAR_METHODS>
<P>Allocation: randomized <BR/>Blinding: double blind<BR/>Design: parallel study, 3 arms<BR/>Sample size at entry 193: auranofin 72; placebo 46, GSTM 75.<BR/>Analysis: completers 90.7% (auranofin 64; placebo 43)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA, multicentre (K=11)<BR/>Patients with active RA<BR/>Age: mean 50.5 y (SD 18)<BR/>Females: 71.5%<BR/>Duration of disease: mean 70 mo. (SD 120)<BR/>RF: 83% <BR/>Concomitant use of steroids: 15%<BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: not in previous 3 mo. No previous gold</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Auranofin 6 mg/day plus placebo injection 1/wk or placebo tablets with GSTM, or placebo tablets and placebo injections.<BR/>Duration of treatment: 21 wks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joints: 68 jnts. 4 pt scale: 0=npne, 3=withdrawal<BR/>Swollen joints: 66 jts. 4 pt scale:0=none, 3=bulging<BR/>Pain<BR/>Patient assessment: 5 pt scale, 5 = worse<BR/>Physician assessment:5 pt scale, 5=worse<BR/>Functional class<BR/>ESR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 5<BR/>Allocation concealment: adequate<BR/>Reported: Baseline means &amp; SD, end of trial, change scores and SD. Results reported at 20 wks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wenger-1983">
<CHAR_METHODS>
<P>Allocation: randomized <BR/>Blinding: First phase double blind, 2nd open label<BR/>Design: parallel study<BR/>Sample size at entry 304: auranofin 152; placebo 152<BR/>Analysis: completers, 60.5% follow-up (auranofin 106, placebo 78)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA, multicentre (K=14)<BR/>Patients with active RA on NSAIDs<BR/>Age: median 53 yrs<BR/>Duration of disease: median 4 yrs<BR/>Females: 69%<BR/>RF: not reported<BR/>Concomitant use of steroids: 13.5%<BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Auranofin 6 mg/day vs identical placebo<BR/>Treatment duration: 26 wk.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joint count<BR/>Swollen joint count<BR/>Physician global efficacy: 4 pt scale 4=worse<BR/>ESR<BR/>Xray results reported in text of review<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Wenger 1983 reports final analysis of data from Katz et al 1982 Wenger results included<BR/>Quality score: 3<BR/>Allocation concealment: unclear<BR/>Only blinded phase included<BR/>Reported: end of trial results. No SDs included<BR/>Converted global efficacy to 4 point scale and combined groups = worse with therapeutic failure. Mean &amp; SD calculated. Numbers of ADRs not requiring withdrawal not reported except for diarrhea.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Baldassare-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dose comparison. No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Borg-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Followup of Borg 1989. No OMERACT outcomes reported in this article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Champion-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dose comparison, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Champion-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dose comparison, no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Egsmose-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long term followup of Borg 1989.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jajic-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lundberg-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Followup of Ward 1983. No OMERACT outcomes reported in this article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bombardier-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davies-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Glennas-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnsen--1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Palmer-1982">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Prouse-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ward-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wenger-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-09-22 01:02:07 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-09-22 01:02:07 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Auranofin vs. placebo - Efficacy</NAME>
<CONT_OUTCOME CHI2="8.935225734483724" CI_END="-2.454808497501244" CI_START="-5.064232130415181" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.7595203139582125" ESTIMABLE="YES" I2="32.85004566986825" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.17725389603791764" P_Q="1.0" P_Z="1.6267857295274502E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="406" TOTAL_2="344" UNITS="" WEIGHT="100.0" Z="5.647626028646334">
<NAME>Tender joint scores</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="-1.3047631156378765" CI_START="-6.295236884362125" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="17.7" MEAN_2="21.5" ORDER="17271" SD_1="11.17" SD_2="10.99" SE="1.2731034366163023" STUDY_ID="STD-Bombardier-1986" TOTAL_1="154" TOTAL_2="149" WEIGHT="27.340448111974958"/>
<CONT_DATA CI_END="11.14475090459233" CI_START="-4.944750904592331" EFFECT_SIZE="3.0999999999999996" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="9.5" ORDER="17272" SD_1="6.4" SD_2="10.1" SE="4.104540169129789" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="8" WEIGHT="2.630292150216225"/>
<CONT_DATA CI_END="-2.9822436301857373" CI_START="-7.697756369814263" EFFECT_SIZE="-5.34" ESTIMABLE="YES" MEAN_1="5.76" MEAN_2="11.1" ORDER="17273" SD_1="6.5" SD_2="6.0" SE="1.2029590280290576" STUDY_ID="STD-Johnsen--1989" TOTAL_1="57" TOTAL_2="51" WEIGHT="30.621843861986562"/>
<CONT_DATA CI_END="0.8892252252304313" CI_START="-19.78922522523043" EFFECT_SIZE="-9.45" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="18.25" ORDER="17274" SD_1="6.52" SD_2="9.83" SE="5.275211844087401" STUDY_ID="STD-Palmer-1982" TOTAL_1="5" TOTAL_2="5" WEIGHT="1.592403779080759"/>
<CONT_DATA CI_END="63.329617399322046" CI_START="-100.32961739932205" EFFECT_SIZE="-18.5" ESTIMABLE="YES" MEAN_1="137.5" MEAN_2="156.0" ORDER="17275" SD_1="101.85" SD_2="84.01" SE="41.75057197212991" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.02542190843838547"/>
<CONT_DATA CI_END="-0.8164803142827175" CI_START="-13.183519685717282" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="30.0" ORDER="17276" SD_1="16.0" SD_2="16.0" SE="3.1549149548114643" STUDY_ID="STD-Ward-1983" TOTAL_1="64" TOTAL_2="43" WEIGHT="4.452026040636454"/>
<CONT_DATA CI_END="0.15968375535273172" CI_START="-4.359683755352731" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="13.4" ORDER="17277" SD_1="8.37" SD_2="7.22" SE="1.1529210603750009" STUDY_ID="STD-Wenger-1983" TOTAL_1="106" TOTAL_2="78" WEIGHT="33.337564147666654"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.61475401356271" CI_END="0.8989795864917156" CI_START="-1.485889691422382" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.29345505246533315" ESTIMABLE="YES" I2="67.97900245077774" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.00803453779885488" P_Q="1.0" P_Z="0.6295630024951369" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="407" TOTAL_2="360" UNITS="" WEIGHT="100.0" Z="0.48234202120832737">
<NAME>Swollen joint scores</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="-0.6817614169936861" CI_START="-5.1182385830063115" EFFECT_SIZE="-2.8999999999999986" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="18.4" ORDER="17278" SD_1="9.93" SD_2="9.77" SE="1.1317751757192964" STUDY_ID="STD-Bombardier-1986" TOTAL_1="154" TOTAL_2="149" WEIGHT="28.896993269864222"/>
<CONT_DATA CI_END="7.843169775776749" CI_START="0.7568302242232501" EFFECT_SIZE="4.3" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="5.7" ORDER="17279" SD_1="6.33" SD_2="6.8" SE="1.8077728997700062" STUDY_ID="STD-Glennas-1997" TOTAL_1="21" TOTAL_2="34" WEIGHT="11.326226475654229"/>
<CONT_DATA CI_END="3.404047139095598" CI_START="-1.1240471390955968" EFFECT_SIZE="1.1400000000000006" ESTIMABLE="YES" MEAN_1="6.82" MEAN_2="5.68" ORDER="17280" SD_1="6.5" SD_2="5.5" SE="1.1551473174783375" STUDY_ID="STD-Johnsen--1989" TOTAL_1="57" TOTAL_2="51" WEIGHT="27.7394749672449"/>
<CONT_DATA CI_END="5.466215697921234" CI_START="-8.266215697921233" EFFECT_SIZE="-1.3999999999999995" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="8.6" ORDER="17281" SD_1="5.13" SD_2="5.92" SE="3.5032356472267177" STUDY_ID="STD-Palmer-1982" TOTAL_1="5" TOTAL_2="5" WEIGHT="3.0160204496942082"/>
<CONT_DATA CI_END="6.3589796996021635" CI_START="-2.3589796996021635" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="18.0" ORDER="17282" SD_1="14.0" SD_2="9.0" SE="2.224010101198409" STUDY_ID="STD-Ward-1983" TOTAL_1="64" TOTAL_2="43" WEIGHT="7.483408859863401"/>
<CONT_DATA CI_END="0.8694084463105898" CI_START="-4.269408446310592" EFFECT_SIZE="-1.700000000000001" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="13.3" ORDER="17283" SD_1="8.27" SD_2="9.15" SE="1.3109467656435305" STUDY_ID="STD-Wenger-1983" TOTAL_1="106" TOTAL_2="78" WEIGHT="21.537875977679043"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.094612947504397" CI_END="-2.7726276732477566" CI_START="-6.5882524352696255" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.680440054258691" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.6638743447404891" P_Q="1.0" P_Z="1.521555136377855E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="432" TOTAL_2="373" UNITS="" WEIGHT="100.0" Z="4.808383690897724">
<NAME>Pain scores</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="4.094612947504397" CI_END="-2.7726276732477566" CI_START="-6.5882524352696255" DF="6.0" EFFECT_SIZE="-4.680440054258691" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.6638743447404891" P_Z="1.521555136377855E-6" STUDIES="7" TAU2="0.0" TOTAL_1="432" TOTAL_2="373" WEIGHT="100.0" Z="4.808383690897724">
<NAME>Pain scores</NAME>
<CONT_DATA CI_END="-2.530016986357984" CI_START="-8.06998301364201" EFFECT_SIZE="-5.299999999999997" ESTIMABLE="YES" MEAN_1="38.6" MEAN_2="43.9" ORDER="17284" SD_1="12.4" SD_2="12.2" SE="1.4132826090128623" STUDY_ID="STD-Bombardier-1986" TOTAL_1="154" TOTAL_2="149" WEIGHT="47.436988899979774"/>
<CONT_DATA CI_END="14.414256439658228" CI_START="-22.414256439658228" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="46.8" MEAN_2="50.8" ORDER="17285" SD_1="22.24" SD_2="17.62" SE="9.395201434775094" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="8" WEIGHT="1.0734033638065754"/>
<CONT_DATA CI_END="6.382568173380355" CI_START="-6.382568173380355" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="50.0" ORDER="17286" SD_1="14.5" SD_2="11.4" SE="3.256472171797665" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" WEIGHT="8.934708772033746"/>
<CONT_DATA CI_END="0.30098830544096433" CI_START="-13.10098830544096" EFFECT_SIZE="-6.399999999999999" ESTIMABLE="YES" MEAN_1="35.42" MEAN_2="41.82" ORDER="17287" SD_1="18.0" SD_2="17.5" SE="3.4189344081307125" STUDY_ID="STD-Johnsen--1989" TOTAL_1="57" TOTAL_2="51" WEIGHT="8.105757479973839"/>
<CONT_DATA CI_END="6.078399226309047" CI_START="-24.078399226309045" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="47.0" ORDER="17288" SD_1="18.06" SD_2="16.3" SE="7.693202194145166" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.6008876346543683"/>
<CONT_DATA CI_END="0.31088391425364925" CI_START="-20.31088391425365" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="42.0" ORDER="17289" SD_1="29.0" SD_2="25.0" SE="5.260751725840161" STUDY_ID="STD-Ward-1983" TOTAL_1="64" TOTAL_2="43" WEIGHT="3.423572514311584"/>
<CONT_DATA CI_END="-0.28293998817775146" CI_START="-7.3170600118222495" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="27.9" MEAN_2="31.7" ORDER="17290" SD_1="13.3" SD_2="11.0" SE="1.7944513468432939" STUDY_ID="STD-Wenger-1983" TOTAL_1="106" TOTAL_2="78" WEIGHT="29.42468133524011"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.00482739093199" CI_END="-0.20603952507583442" CI_START="-0.5205144703162431" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3632769976960388" ESTIMABLE="YES" I2="83.34003534685782" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-09-22 01:02:07 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0024727823718615483" P_Q="1.0" P_Z="5.9475540200545185E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="346" TOTAL_2="324" UNITS="" WEIGHT="100.0" Z="4.528245207908449">
<NAME>Physician global assessment</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.15699830136420118" CI_START="-0.3969983013642014" EFFECT_SIZE="-0.1200000000000001" ESTIMABLE="YES" MEAN_1="-6.78" MEAN_2="-6.66" ORDER="17291" SD_1="1.24" SD_2="1.22" SE="0.14132826090128622" STUDY_ID="STD-Bombardier-1986" TOTAL_1="154" TOTAL_2="149" WEIGHT="32.222400946324655"/>
<CONT_DATA CI_END="-0.013828844769250809" CI_START="-0.5061711552307496" EFFECT_SIZE="-0.26000000000000023" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="2.74" ORDER="17292" SD_1="0.54" SD_2="0.69" SE="0.12559983610541625" STUDY_ID="STD-Ward-1983" TOTAL_1="62" TOTAL_2="43" WEIGHT="40.79789741351295"/>
<CONT_DATA CI_END="-0.5072825313086202" CI_START="-1.1127174686913794" EFFECT_SIZE="-0.8099999999999998" ESTIMABLE="YES" MEAN_1="1.99" MEAN_2="2.8" ORDER="17293" SD_1="1.24" SD_2="1.26" SE="0.15445052617250948" STUDY_ID="STD-Wenger-1983" TOTAL_1="130" TOTAL_2="132" WEIGHT="26.979701640162393"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2737258671142" CI_END="-0.17244008280549178" CI_START="-0.6493335271151968" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.41088680496034424" ESTIMABLE="YES" I2="8.361294690672754" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2008-09-22 01:02:07 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.35131634910787646" P_Q="1.0" P_Z="7.318194142988904E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="280" TOTAL_2="248" UNITS="" WEIGHT="100.0" Z="3.3773722371491193">
<NAME>Patient Global assessment</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.2739966027284032" CI_START="-0.8339966027284019" EFFECT_SIZE="-0.27999999999999936" ESTIMABLE="YES" MEAN_1="-6.39" MEAN_2="-6.11" ORDER="17294" SD_1="2.48" SD_2="2.44" SE="0.28265652180257245" STUDY_ID="STD-Bombardier-1986" TOTAL_1="154" TOTAL_2="149" WEIGHT="18.52543908905357"/>
<CONT_DATA CI_END="4.324874184509674" CI_START="-7.964874184509674" EFFECT_SIZE="-1.8200000000000003" ESTIMABLE="YES" MEAN_1="-61.6" MEAN_2="-59.78" ORDER="17295" SD_1="16.0" SD_2="16.5" SE="3.135197500045744" STUDY_ID="STD-Johnsen--1989" TOTAL_1="57" TOTAL_2="51" WEIGHT="0.15057633526323766"/>
<CONT_DATA CI_END="-0.29079856695116046" CI_START="-1.7492014330488392" EFFECT_SIZE="-1.0199999999999998" ESTIMABLE="YES" MEAN_1="-2.05" MEAN_2="-1.03" ORDER="17296" SD_1="0.75" SD_2="0.36" SE="0.37204838395025985" STUDY_ID="STD-Palmer-1982" TOTAL_1="5" TOTAL_2="5" WEIGHT="10.692707491688395"/>
<CONT_DATA CI_END="-0.06627812104353137" CI_START="-0.6337218789564688" EFFECT_SIZE="-0.3500000000000001" ESTIMABLE="YES" MEAN_1="2.42" MEAN_2="2.77" ORDER="17297" SD_1="0.66" SD_2="0.78" SE="0.14475872066753812" STUDY_ID="STD-Ward-1983" TOTAL_1="64" TOTAL_2="43" WEIGHT="70.63127708399479"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.351711750261094" CI_END="-0.002225232035874658" CI_START="-0.2826267760027051" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.14242600401928987" ESTIMABLE="YES" I2="8.082147220343627" I2_Q="52.292838304802565" ID="CMP-001.06" MODIFIED="2008-09-22 01:02:07 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.36049453304130985" P_Q="0.1229323683731588" P_Z="0.046472966844583984" Q="4.192242692571114" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="498" TOTAL_2="486" UNITS="" WEIGHT="300.0" Z="1.9910720489669393">
<NAME>Global Assessment of function</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="1.3158573863800734E-30" CI_END="0.010781329952838703" CI_START="-0.2707813299528386" DF="1.0" EFFECT_SIZE="-0.12999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.9999999999999991" P_Z="0.0703165968676661" STUDIES="2" TAU2="0.0" TOTAL_1="185" TOTAL_2="183" WEIGHT="100.0" Z="1.8098658257850146">
<NAME>Functional status: Health Assessment Questionnaire</NAME>
<CONT_DATA CI_END="0.02273407109638012" CI_START="-0.28273407109637994" EFFECT_SIZE="-0.1299999999999999" ESTIMABLE="YES" MEAN_1="1.09" MEAN_2="1.22" ORDER="17298" SD_1="0.62" SD_2="0.73" SE="0.07792697840425991" STUDY_ID="STD-Bombardier-1986" TOTAL_1="154" TOTAL_2="149" WEIGHT="84.96073706058691"/>
<CONT_DATA CI_END="0.23302103231302868" CI_START="-0.4930210323130289" EFFECT_SIZE="-0.13000000000000012" ESTIMABLE="YES" MEAN_1="0.97" MEAN_2="1.1" ORDER="17299" SD_1="0.76" SD_2="0.73" SE="0.18521821583278691" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" WEIGHT="15.039262939413092"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.182188942612802" CI_START="-7.582188942612801" DF="0.0" EFFECT_SIZE="-3.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="1.0" P_Z="0.1523666311792935" STUDIES="1" TAU2="0.0" TOTAL_1="154" TOTAL_2="149" WEIGHT="100.0" Z="1.4312218922237236">
<NAME>Functional status: Keitel Assessment</NAME>
<CONT_DATA CI_END="1.182188942612802" CI_START="-7.582188942612801" EFFECT_SIZE="-3.1999999999999993" ESTIMABLE="YES" MEAN_1="28.5" MEAN_2="31.7" ORDER="17300" SD_1="12.41" SD_2="24.41" SE="2.2358517693074713" STUDY_ID="STD-Bombardier-1986" TOTAL_1="154" TOTAL_2="149" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1594690576899805" CI_END="0.23334270401804713" CI_START="-3.069598268570333" DF="1.0" EFFECT_SIZE="-1.418127782276143" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" NO="3" P_CHI2="0.6896460177338009" P_Z="0.0923686972076716" STUDIES="2" TAU2="0.0" TOTAL_1="159" TOTAL_2="154" WEIGHT="100.0" Z="1.683033031352501">
<NAME>Functional status: 50 ft/15 m walk time</NAME>
<CONT_DATA CI_END="0.33498118012768696" CI_START="-3.0349811801276863" EFFECT_SIZE="-1.3499999999999996" ESTIMABLE="YES" MEAN_1="14.26" MEAN_2="15.61" ORDER="17301" SD_1="6.2" SD_2="8.54" SE="0.85970007276593" STUDY_ID="STD-Bombardier-1986" TOTAL_1="154" TOTAL_2="149" WEIGHT="96.0619779031131"/>
<CONT_DATA CI_END="5.242077241633044" CI_START="-11.402077241633044" EFFECT_SIZE="-3.08" ESTIMABLE="YES" MEAN_1="11.62" MEAN_2="14.7" ORDER="17302" SD_1="5.05" SD_2="8.04" SE="4.246035798247584" STUDY_ID="STD-Palmer-1982" TOTAL_1="5" TOTAL_2="5" WEIGHT="3.93802209688689"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="18.551625467667108" CI_END="-5.9176419755978635" CI_START="-12.158772733236589" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.038207354417226" ESTIMABLE="YES" I2="67.65782054808534" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2008-09-22 01:02:07 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.004991867098011471" P_Q="1.0" P_Z="1.3730579472882188E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="387" TOTAL_2="349" UNITS="" WEIGHT="100.00000000000001" Z="5.676715193887381">
<NAME>ESR</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.6633349658043137" CI_START="-10.423334965804319" EFFECT_SIZE="-4.880000000000003" ESTIMABLE="YES" MEAN_1="35.69" MEAN_2="40.57" ORDER="17303" SD_1="24.82" SD_2="24.41" SE="2.8282840957943285" STUDY_ID="STD-Bombardier-1986" TOTAL_1="154" TOTAL_2="149" WEIGHT="31.69015234547599"/>
<CONT_DATA CI_END="-12.507670936080046" CI_START="-24.03232906391996" EFFECT_SIZE="-18.270000000000003" ESTIMABLE="YES" MEAN_1="18.36" MEAN_2="36.63" ORDER="17304" SD_1="17.0" SD_2="13.5" SE="2.9400178316400054" STUDY_ID="STD-Johnsen--1989" TOTAL_1="57" TOTAL_2="51" WEIGHT="29.32719053814924"/>
<CONT_DATA CI_END="-0.18985084743502512" CI_START="-38.37014915256498" EFFECT_SIZE="-19.28" ESTIMABLE="YES" MEAN_1="36.72" MEAN_2="56.0" ORDER="17305" SD_1="39.67" SD_2="35.67" SE="9.740050992337428" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" WEIGHT="2.672070599923174"/>
<CONT_DATA CI_END="5.4603106035900915" CI_START="-41.96031060359009" EFFECT_SIZE="-18.25" ESTIMABLE="YES" MEAN_1="23.25" MEAN_2="41.5" ORDER="17306" SD_1="17.81" SD_2="20.36" SE="12.097319537814977" STUDY_ID="STD-Palmer-1982" TOTAL_1="5" TOTAL_2="5" WEIGHT="1.7321762724889096"/>
<CONT_DATA CI_END="20.804612948437136" CI_START="-30.804612948437136" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="44.25" MEAN_2="49.25" ORDER="17307" SD_1="33.9" SD_2="24.17" SE="13.165860777024797" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.4624191760019438"/>
<CONT_DATA CI_END="2.50025823180434" CI_START="-20.500258231804338" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="51.0" ORDER="17308" SD_1="23.0" SD_2="26.0" SE="5.8675865079751" STUDY_ID="STD-Ward-1983" TOTAL_1="35" TOTAL_2="35" WEIGHT="7.362942131595324"/>
<CONT_DATA CI_END="3.9492048259208303" CI_START="-8.349204825920829" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="31.2" MEAN_2="33.4" ORDER="17309" SD_1="23.9" SD_2="16.39" SE="3.137407051570831" STUDY_ID="STD-Wenger-1983" TOTAL_1="96" TOTAL_2="69" WEIGHT="25.753048936365428"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Auranofin vs. placebo - Withdrawals and dropouts</NAME>
<DICH_OUTCOME CHI2="95.19014770174216" CI_END="0.7546503270844362" CI_START="0.5031857713045607" CI_STUDY="95" CI_TOTAL="95" DF="27.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6162218000843698" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="289" I2="71.63572002787653" I2_Q="91.10745095435296" ID="CMP-002.01" LOG_CI_END="-0.12225423538437594" LOG_CI_START="-0.2982716480303589" LOG_EFFECT_SIZE="-0.21026294170736742" METHOD="PETO" NO="1" P_CHI2="1.5643855100222481E-9" P_Q="2.252345151498858E-7" P_Z="2.8328680720426755E-6" Q="33.73610856235329" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2156" TOTAL_2="2040" WEIGHT="400.0" Z="4.682579829289296">
<NAME>Withdrawals: Global reasons</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="28.235103905410774" CI_END="0.8271870355925962" CI_START="0.4640189769050251" DF="7.0" EFFECT_SIZE="0.61954054101792" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="156" I2="75.2081663185997" ID="CMP-002.01.01" LOG_CI_END="-0.08239628084432814" LOG_CI_START="-0.3334642578145011" LOG_EFFECT_SIZE="-0.20793026932941466" NO="1" P_CHI2="1.993325522027245E-4" P_Z="0.0011686698070390385" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="100.0" Z="3.2464183134735793">
<NAME>Withdrawals: total</NAME>
<DICH_DATA CI_END="3.67171864110945" CI_START="1.0508342390387317" EFFECT_SIZE="1.9642728079863485" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="16" LOG_CI_END="0.5648693943987013" LOG_CI_START="0.021534214840464486" LOG_EFFECT_SIZE="0.29320180461958284" ORDER="17310" O_E="6.627831715210355" SE="0.31915777402502366" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="9.817234053637106" WEIGHT="21.352414698465218"/>
<DICH_DATA CI_END="1.3061572534832575" CI_START="0.01100381030811838" EFFECT_SIZE="0.11988622377030089" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11599546653228708" LOG_CI_START="-1.9584569049097194" LOG_EFFECT_SIZE="-0.9212307191887161" ORDER="17311" O_E="-1.4285714285714286" SE="1.2185435916898848" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.673469387755102" WEIGHT="1.4647911596587442"/>
<DICH_DATA CI_END="0.5534528351854283" CI_START="0.07341130658432292" EFFECT_SIZE="0.20156809212710283" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="28" LOG_CI_END="-0.2569193834419415" LOG_CI_START="-1.1342370462280738" LOG_EFFECT_SIZE="-0.6955782148350076" ORDER="17312" O_E="-6.030769230769231" SE="0.5153407379130445" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="3.7653994082840243" WEIGHT="8.189717106851411"/>
<DICH_DATA CI_END="0.9515420937839603" CI_START="0.20101984728393596" EFFECT_SIZE="0.43735437162178725" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.021571994876975517" LOG_CI_START="-0.6967610612841751" LOG_EFFECT_SIZE="-0.3591665280805753" ORDER="17313" O_E="-5.257575757575758" SE="0.39660939984737065" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="6.357318851246678" WEIGHT="13.827123580892813"/>
<DICH_DATA CI_END="0.7123664064129571" CI_START="0.0768080465954149" EFFECT_SIZE="0.23391338597176234" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.14729656907049926" LOG_CI_START="-1.1145932798522187" LOG_EFFECT_SIZE="-0.6309449244613591" ORDER="17314" O_E="-4.5" SE="0.5681948761091234" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="3.097457627118644" WEIGHT="6.736948452467458"/>
<DICH_DATA CI_END="5.521541001777798" CI_START="0.18110886067458795" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.7420603014918854" LOG_CI_START="-0.7420603014918854" LOG_EFFECT_SIZE="0.0" ORDER="17315" O_E="0.0" SE="0.8717797887081348" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="1.3157894736842104" WEIGHT="2.8618328079457123"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17316" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7172313063739177" CI_START="0.5605939031278366" EFFECT_SIZE="1.4435571366832494" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.5702195861041535" LOG_CI_START="-0.25135162982285353" LOG_EFFECT_SIZE="0.15943397814064997" ORDER="17317" O_E="1.5762711864406782" SE="0.482594999078632" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="4.293726382781253" WEIGHT="9.33882454324495"/>
<DICH_DATA CI_END="0.7406479933788268" CI_START="0.2834562540829424" EFFECT_SIZE="0.4581935243946712" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="62" LOG_CI_END="-0.13038814945067995" LOG_CI_START="-0.5475139564407046" LOG_EFFECT_SIZE="-0.3389510529456922" ORDER="17318" O_E="-13.0" SE="0.2450217638319858" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="16.65676567656766" WEIGHT="36.228347650473694"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.059124894047148" CI_END="0.4431489748203291" CI_START="0.21127802483740257" DF="7.0" EFFECT_SIZE="0.30598633974208556" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="100" I2="46.397633403514895" ID="CMP-002.01.02" LOG_CI_END="-0.35345025105420685" LOG_CI_START="-0.6751456718457488" LOG_EFFECT_SIZE="-0.5142979614499777" NO="2" P_CHI2="0.0706809191994262" P_Z="3.684687311435576E-10" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="100.00000000000001" Z="6.266831397749435">
<NAME>Withdrawals: lack of effect</NAME>
<DICH_DATA CI_END="3.061581275182044" CI_START="0.3054188222144093" EFFECT_SIZE="0.9669873562667659" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.48594579305300517" LOG_CI_START="-0.515104201948994" LOG_EFFECT_SIZE="-0.014579204447994413" ORDER="17319" O_E="-0.09708737864077666" SE="0.5880217223415672" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="2.8920996997158746" WEIGHT="10.327096191537004"/>
<DICH_DATA CI_END="2.3105256186969876" CI_START="0.007776773102154707" EFFECT_SIZE="0.1340463855660498" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3637107882613687" LOG_CI_START="-2.109200571987357" LOG_EFFECT_SIZE="-0.8727448918629943" ORDER="17320" O_E="-0.9523809523809523" SE="1.452600374118757" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.473922902494331" WEIGHT="1.6922817017380796"/>
<DICH_DATA CI_END="1.5061503030221033" CI_START="0.15212469791989636" EFFECT_SIZE="0.4786675880704665" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.1778683135087568" LOG_CI_START="-0.817800271156964" LOG_EFFECT_SIZE="-0.3199659788241036" ORDER="17321" O_E="-2.153846153846154" SE="0.5848606552716266" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="2.9234467455621305" WEIGHT="10.439030077428493"/>
<DICH_DATA CI_END="0.5277986725691693" CI_START="0.09309181003386194" EFFECT_SIZE="0.22166130416230437" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="20" LOG_CI_END="-0.27753170637934504" LOG_CI_START="-1.0310885253941406" LOG_EFFECT_SIZE="-0.6543101158867428" ORDER="17322" O_E="-7.6893939393939394" SE="0.4426430056557044" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="5.103789894083093" WEIGHT="18.224589277737774"/>
<DICH_DATA CI_END="0.36296076973683505" CI_START="0.02456237503271634" EFFECT_SIZE="0.0944202231963023" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.4401403127256591" LOG_CI_START="-1.6097296418576899" LOG_EFFECT_SIZE="-1.0249349772916745" ORDER="17323" O_E="-5.0" SE="0.6870225614927068" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="2.11864406779661" WEIGHT="7.565244409075633"/>
<DICH_DATA CI_END="1.5730039643424976" CI_START="0.030409897608994877" EFFECT_SIZE="0.21871188695221477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.19672981714960697" LOG_CI_START="-1.5169850421354925" LOG_EFFECT_SIZE="-0.6601276124929427" ORDER="17324" O_E="-1.5" SE="1.0066445913694333" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.9868421052631579" WEIGHT="3.523811211595756"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17325" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.544442910238792" CI_START="0.33351771073589626" EFFECT_SIZE="1.5862551270840717" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.8776271765249168" LOG_CI_START="-0.47688109886694735" LOG_EFFECT_SIZE="0.2003730388289847" ORDER="17326" O_E="0.7288135593220337" SE="0.7956448658892797" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="1.5796521777561712" WEIGHT="5.640614668457499"/>
<DICH_DATA CI_END="0.44222612611753087" CI_START="0.1421321632233125" EFFECT_SIZE="0.25070810904107205" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="46" LOG_CI_END="-0.35435560347258116" LOG_CI_START="-0.8473076340371013" LOG_EFFECT_SIZE="-0.6008316187548413" ORDER="17327" O_E="-16.5" SE="0.2895624629055047" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="11.926567656765677" WEIGHT="42.587332462429764"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.446716133067526" CI_END="8.694226272768045" CI_START="0.8632221289171992" DF="4.0" EFFECT_SIZE="2.7395343605194435" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.9392309387919932" LOG_CI_START="-0.06387743493375826" LOG_EFFECT_SIZE="0.4376767519291174" NO="3" P_CHI2="0.4860266802836626" P_Z="0.08720210430181682" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="99.99999999999997" Z="1.7103449499985368">
<NAME>Withdrawals: concurrent illness</NAME>
<DICH_DATA CI_END="115.72835145257443" CI_START="0.4483782603275017" EFFECT_SIZE="7.203476722727368" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0634397666532376" LOG_CI_START="-0.3483554523854607" LOG_EFFECT_SIZE="0.8575421571338884" ORDER="17328" O_E="0.9838187702265373" SE="1.4167004502422085" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="0.4982461323304004" WEIGHT="17.29875515746172"/>
<DICH_DATA CI_END="7.502895371046411" CI_START="0.0029278971387777363" EFFECT_SIZE="0.14821506633752016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8752288901934648" LOG_CI_START="-2.5334441847331535" LOG_EFFECT_SIZE="-0.8291076472698444" ORDER="17329" O_E="-0.47619047619047616" SE="2.002271437415744" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.24943310657596368" WEIGHT="8.660141963653691"/>
<DICH_DATA CI_END="24.382674490273295" CI_START="0.6498170163284174" EFFECT_SIZE="3.9804870037944355" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3870813408501639" LOG_CI_START="-0.1872089202597752" LOG_EFFECT_SIZE="0.5999362102951942" ORDER="17330" O_E="1.6153846153846154" SE="0.9247458922384523" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="1.169378698224852" WEIGHT="40.60000564847089"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17331" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.372456241572294" CI_START="0.06107819042208459" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2141138383697911" LOG_CI_START="-1.2141138383697911" LOG_EFFECT_SIZE="0.0" ORDER="17332" O_E="0.0" SE="1.4263529572376852" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.4915254237288136" WEIGHT="17.06541688338476"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17333" O_E="0.0" SE="0.0" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17334" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="90.63905415415354" CI_START="0.30093809533786875" EFFECT_SIZE="5.222714267541057" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9573153648851829" LOG_CI_START="-0.5215228320412431" LOG_EFFECT_SIZE="0.7178962664219699" ORDER="17335" O_E="0.7796610169491525" SE="1.4560818273215526" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.4716593375024861" WEIGHT="16.375680347028926"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17336" O_E="0.0" SE="0.0" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.713094206863424" CI_END="2.4562288987597762" CI_START="0.9406922205860913" DF="6.0" EFFECT_SIZE="1.5200511231672649" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="30" I2="64.10000490791208" ID="CMP-002.01.04" LOG_CI_END="0.39026883675093005" LOG_CI_START="-0.02655244752444674" LOG_EFFECT_SIZE="0.18185819461324165" NO="4" P_CHI2="0.01039758457690898" P_Z="0.08721857931424017" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="100.00000000000001" Z="1.7102558107370898">
<NAME>Withdrawals: adverse reactions</NAME>
<DICH_DATA CI_END="6.0921822405301675" CI_START="1.0781483814357022" EFFECT_SIZE="2.562864885638517" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.7847728862714964" LOG_CI_START="0.03267853525159039" LOG_EFFECT_SIZE="0.4087257107615434" ORDER="17337" O_E="4.822006472491909" SE="0.441783944716173" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="5.123658109990469" WEIGHT="30.715325450487455"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17338" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6023820224884169" CI_START="0.0668833967474897" EFFECT_SIZE="0.2007220859886825" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.22012799771469632" LOG_CI_START="-1.1746816788819734" LOG_EFFECT_SIZE="-0.6974048382983349" ORDER="17339" O_E="-5.107692307692307" SE="0.5607095574345861" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="3.1807100591715978" WEIGHT="19.067732962236345"/>
<DICH_DATA CI_END="12.182365199470006" CI_START="0.8209839557544286" EFFECT_SIZE="3.162518991548663" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.0857316145166829" LOG_CI_START="-0.0856653300856793" LOG_EFFECT_SIZE="0.5000331422155018" ORDER="17340" O_E="2.4318181818181817" SE="0.6880843637678205" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="2.112110434672891" WEIGHT="12.661687801114631"/>
<DICH_DATA CI_END="9.438191369663617" CI_START="0.24992796280497898" EFFECT_SIZE="1.5358606517466233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9748887788923221" LOG_CI_START="-0.6021851507862588" LOG_EFFECT_SIZE="0.1863518140530317" ORDER="17341" O_E="0.5" SE="0.9263810329350542" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="1.1652542372881356" WEIGHT="6.985470607626315"/>
<DICH_DATA CI_END="27.752369818120354" CI_START="0.3873908158667119" EFFECT_SIZE="3.2788737679386735" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4433000741249682" LOG_CI_START="-0.4118506796047452" LOG_EFFECT_SIZE="0.5157246972601115" ORDER="17342" O_E="1.0" SE="1.0897247358851685" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.8421052631578947" WEIGHT="5.048255887922864"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17343" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.252535623814373" CI_START="0.4981980690742032" EFFECT_SIZE="2.6646924263778766" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.1538921351844433" LOG_CI_START="-0.3025979600432771" LOG_EFFECT_SIZE="0.4256470875705831" ORDER="17344" O_E="1.3389830508474576" SE="0.8555494916790115" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="1.3661856672485806" WEIGHT="8.190015120936625"/>
<DICH_DATA CI_END="6.324833010612492" CI_START="0.6307018771976373" EFFECT_SIZE="1.9972691488016538" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8010490636775947" LOG_CI_START="-0.20017587638679427" LOG_EFFECT_SIZE="0.3004365936454002" ORDER="17345" O_E="2.0" SE="0.5881244859372071" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="2.891089108910891" WEIGHT="17.331512169675772"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="45.29550336319803" CI_END="3.3154074728938934" CI_START="1.515060958132895" CI_STUDY="95" CI_TOTAL="95" DF="34.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.241214943391995" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="31" I2="24.937361381384868" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5205369120331775" LOG_CI_START="0.18043010692951394" LOG_EFFECT_SIZE="0.3504835094813458" METHOD="PETO" NO="2" P_CHI2="0.09325316255880756" P_Q="0.4688232295602318" P_Z="5.35594453131811E-5" Q="6.626065651665222" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4281" TOTAL_2="4046" WEIGHT="800.0" Z="4.0395254987577465">
<NAME>Withdrawals: System specific adverse reactions</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="10.038852349885687" CI_END="6.515981946419243" CI_START="1.3622929735819944" DF="6.0" EFFECT_SIZE="2.9793751730176687" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" I2="40.232211901509615" ID="CMP-002.02.01" LOG_CI_END="0.8139798723551085" LOG_CI_START="0.13427051662764888" LOG_EFFECT_SIZE="0.4741251944913787" NO="1" P_CHI2="0.12302545563015088" P_Z="0.006251101482985448" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="100.0" Z="2.73431076837717">
<NAME>Withdrawals: gastrointestinal -all signs and symptoms</NAME>
<DICH_DATA CI_END="17.96354520959822" CI_START="1.2713735429445807" EFFECT_SIZE="4.77895136164536" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.2543920513193036" LOG_CI_START="0.10427316959819062" LOG_EFFECT_SIZE="0.6793326104587472" ORDER="17346" O_E="3.4271844660194173" SE="0.6755855243032648" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="2.1909846209968746" WEIGHT="34.926979448042694"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17347" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3887484476335414" CI_START="0.01390826495649317" EFFECT_SIZE="0.13897870832471382" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.14262358648749204" LOG_CI_START="-1.8567270444737611" LOG_EFFECT_SIZE="-0.8570517289931345" ORDER="17348" O_E="-1.4307692307692308" SE="1.1744284575718793" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="0.7250147928994083" WEIGHT="11.55762415146623"/>
<DICH_DATA CI_END="45.279014528638186" CI_START="1.28602842339801" EFFECT_SIZE="7.630864935725186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6558969661167897" LOG_CI_START="0.10925056733509181" LOG_EFFECT_SIZE="0.8825737667259408" ORDER="17349" O_E="2.462121212121212" SE="0.9085077506675181" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="1.2115538627075753" WEIGHT="19.313653075178102"/>
<DICH_DATA CI_END="16.372456241572294" CI_START="0.06107819042208459" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2141138383697911" LOG_CI_START="-1.2141138383697911" LOG_EFFECT_SIZE="0.0" ORDER="17350" O_E="0.0" SE="1.4263529572376852" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.4915254237288136" WEIGHT="7.835517514931583"/>
<DICH_DATA CI_END="102.29824003226075" CI_START="0.8544440687358337" EFFECT_SIZE="9.349231221746512" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0098681620518235" LOG_CI_START="-0.06831636060199149" LOG_EFFECT_SIZE="0.9707759007249159" ORDER="17351" O_E="1.5" SE="1.2207358757861475" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.6710526315789473" WEIGHT="10.697401180775469"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17352" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="286.4553993926163" CI_START="0.09256861994587726" EFFECT_SIZE="5.149444727135109" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4570570126715765" LOG_CI_START="-1.033536210877585" LOG_EFFECT_SIZE="0.7117604008969959" ORDER="17353" O_E="0.38983050847457623" SE="2.0503917382279018" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.23786268313702963" WEIGHT="3.79182261973311"/>
<DICH_DATA CI_END="18.9494367343563" CI_START="0.20198102608274374" EFFECT_SIZE="1.9563810148576175" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2775963052383108" LOG_CI_START="-0.6946894258731487" LOG_EFFECT_SIZE="0.2914534396825809" ORDER="17354" O_E="0.5" SE="1.1585304014266955" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="0.745049504950495" WEIGHT="11.877002009872822"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.701790439042076" CI_END="7.060565353068795" CI_START="1.289708963453326" DF="6.0" EFFECT_SIZE="3.017627283628782" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" I2="38.15574519261188" ID="CMP-002.02.02" LOG_CI_END="0.8488394772398808" LOG_CI_START="0.11049171818573572" LOG_EFFECT_SIZE="0.4796655977128082" NO="2" P_CHI2="0.13778516100676907" P_Z="0.010878724729688656" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="100.0" Z="2.5465704598178114">
<NAME>Withdrawals: diarrhea</NAME>
<DICH_DATA CI_END="18.251949520477755" CI_START="1.1052284143856486" EFFECT_SIZE="4.491388786106645" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.2613092589715262" LOG_CI_START="0.04345204169169132" LOG_EFFECT_SIZE="0.6523806503316087" ORDER="17355" O_E="2.935275080906149" SE="0.7153753579206268" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="1.9540336916149903" WEIGHT="36.756078791081016"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17356" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3887484476335414" CI_START="0.01390826495649317" EFFECT_SIZE="0.13897870832471382" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.14262358648749204" LOG_CI_START="-1.8567270444737611" LOG_EFFECT_SIZE="-0.8570517289931345" ORDER="17357" O_E="-1.4307692307692308" SE="1.1744284575718793" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="0.7250147928994083" WEIGHT="13.637789853298303"/>
<DICH_DATA CI_END="72.35640564646549" CI_START="0.7556208277024572" EFFECT_SIZE="7.394187387682098" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8594769848506083" LOG_CI_START="-0.12169607982433715" LOG_EFFECT_SIZE="0.8688904525131356" ORDER="17358" O_E="1.4772727272727273" SE="1.1637508651548978" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.7383800706580026" WEIGHT="13.889195550378968"/>
<DICH_DATA CI_END="16.372456241572294" CI_START="0.06107819042208459" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2141138383697911" LOG_CI_START="-1.2141138383697911" LOG_EFFECT_SIZE="0.0" ORDER="17359" O_E="0.0" SE="1.4263529572376852" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.4915254237288136" WEIGHT="9.245770571879918"/>
<DICH_DATA CI_END="102.29824003226075" CI_START="0.8544440687358337" EFFECT_SIZE="9.349231221746512" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0098681620518235" LOG_CI_START="-0.06831636060199149" LOG_EFFECT_SIZE="0.9707759007249159" ORDER="17360" O_E="1.5" SE="1.2207358757861475" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.6710526315789473" WEIGHT="12.622742128306111"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17361" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="286.4553993926163" CI_START="0.09256861994587726" EFFECT_SIZE="5.149444727135109" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4570570126715765" LOG_CI_START="-1.033536210877585" LOG_EFFECT_SIZE="0.7117604008969959" ORDER="17362" O_E="0.38983050847457623" SE="2.0503917382279018" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.23786268313702963" WEIGHT="4.474282895100276"/>
<DICH_DATA CI_END="119.46404627755847" CI_START="0.4631193767300389" EFFECT_SIZE="7.438152637161421" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0772372203244625" LOG_CI_START="-0.3343070479180343" LOG_EFFECT_SIZE="0.8714650862032141" ORDER="17363" O_E="1.0" SE="1.4165530405022932" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="0.49834983498349833" WEIGHT="9.37414020995541"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.317609205362855" CI_END="3.2257520697461155" CI_START="0.7545406651161233" DF="5.0" EFFECT_SIZE="1.5601157367983778" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" I2="46.33816583419067" ID="CMP-002.02.03" LOG_CI_END="0.5086309846031672" LOG_CI_START="-0.12231734944753017" LOG_EFFECT_SIZE="0.19315681757781852" NO="3" P_CHI2="0.09704697617027869" P_Z="0.230125321693035" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="100.00000000000001" Z="1.2000361531677433">
<NAME>Withdrawals: mucosal / cutaneous adverse reactions</NAME>
<DICH_DATA CI_END="3.7682302772291396" CI_START="0.11047811860183512" EFFECT_SIZE="0.645218561021571" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5761374347456019" LOG_CI_START="-0.9567237302277461" LOG_EFFECT_SIZE="-0.19029314774107223" ORDER="17364" O_E="-0.5404530744336569" SE="0.9004102360904855" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="1.2334431940426849" WEIGHT="16.942673939131968"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17365" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5663800704643305" CI_START="0.08279023811585215" EFFECT_SIZE="0.3601124532887848" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19489714883187295" LOG_CI_START="-1.0820208683159946" LOG_EFFECT_SIZE="-0.44356185974206086" ORDER="17366" O_E="-1.8153846153846156" SE="0.7500679641187836" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="1.7774556213017754" WEIGHT="24.415271962618693"/>
<DICH_DATA CI_END="19.50221252202353" CI_START="1.4936677951613306" EFFECT_SIZE="5.397205460100492" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.2900838847777838" LOG_CI_START="0.17425401731131449" LOG_EFFECT_SIZE="0.732168951044549" ORDER="17367" O_E="3.924242424242424" SE="0.655443987596729" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="2.3277097834696723" WEIGHT="31.973606953875937"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17368" O_E="0.0" SE="0.0" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="17369" O_E="0.5" SE="2.0" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.25" WEIGHT="3.4340199088539554"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17370" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.222680685394973" CI_START="0.12262409252738019" EFFECT_SIZE="1.2733496062848866" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1213195102823514" LOG_CI_START="-0.911424193571706" LOG_EFFECT_SIZE="0.10494765835532262" ORDER="17371" O_E="0.1694915254237288" SE="1.194043713887489" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.7013899630963695" WEIGHT="9.634348388573095"/>
<DICH_DATA CI_END="19.682687192761332" CI_START="0.3829926706569964" EFFECT_SIZE="2.7456010150169163" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2940843905038304" LOG_CI_START="-0.41680953705926166" LOG_EFFECT_SIZE="0.43863742672228434" ORDER="17372" O_E="1.0" SE="1.004987562112089" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="0.9900990099009901" WEIGHT="13.600078846946358"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.162868021315437" CI_END="7.27062523376671" CI_START="0.5273282097918112" DF="4.0" EFFECT_SIZE="1.9580617427929505" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="0.8615717594008762" LOG_CI_START="-0.2779189951596871" LOG_EFFECT_SIZE="0.2918263821205944" NO="4" P_CHI2="0.5309493103380429" P_Z="0.31542529494405525" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="100.0" Z="1.0039031846564912">
<NAME>Withdrawals: renal adverse reactions</NAME>
<DICH_DATA CI_END="360.8975481068137" CI_START="0.14194886593069161" EFFECT_SIZE="7.157443515035897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5573839315266773" LOG_CI_START="-0.8478680728247049" LOG_EFFECT_SIZE="0.8547579293509864" ORDER="17373" O_E="0.49190938511326865" SE="2.000261883625278" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="0.24993454195075457" WEIGHT="11.197552238038423"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17374" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.480839486483617" CI_START="0.0029208680535513488" EFFECT_SIZE="0.14781929870560026" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8739503363524559" LOG_CI_START="-2.534488061276654" LOG_EFFECT_SIZE="-0.8302688624620991" ORDER="17375" O_E="-0.47692307692307695" SE="2.0021335868095163" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="0.2494674556213018" WEIGHT="11.176625864545192"/>
<DICH_DATA CI_END="117.69207836199989" CI_START="0.45047026327397854" EFFECT_SIZE="7.281262357928863" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0707472322618763" LOG_CI_START="-0.3463338726588839" LOG_EFFECT_SIZE="0.8622066798014962" ORDER="17376" O_E="0.9848484848484849" SE="1.4198054057748888" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.49606929811648753" WEIGHT="22.224866703062187"/>
<DICH_DATA CI_END="16.372456241572294" CI_START="0.06107819042208459" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2141138383697911" LOG_CI_START="-1.2141138383697911" LOG_EFFECT_SIZE="0.0" ORDER="17377" O_E="0.0" SE="1.4263529572376852" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.4915254237288136" WEIGHT="22.0212923174573"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17378" O_E="0.0" SE="0.0" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17379" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17380" O_E="0.0" SE="0.0" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="18.9494367343563" CI_START="0.20198102608274374" EFFECT_SIZE="1.9563810148576175" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2775963052383108" LOG_CI_START="-0.6946894258731487" LOG_EFFECT_SIZE="0.2914534396825809" ORDER="17381" O_E="0.5" SE="1.1585304014266955" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="0.745049504950495" WEIGHT="33.37966287689691"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals: liver adverse reactions</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.249695018532572" CI_END="16.65199300748589" CI_START="0.8370225932357195" DF="3.0" EFFECT_SIZE="3.733375733792261" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-002.02.06" LOG_CI_END="1.221466219845599" LOG_CI_START="-0.07726281920485961" LOG_EFFECT_SIZE="0.5721017003203697" NO="6" P_CHI2="0.7411117903752146" P_Z="0.08421020769449417" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="100.0" Z="1.726763157528022">
<NAME>Withdrawals: hematology adverse reactions</NAME>
<DICH_DATA CI_END="115.72835145257443" CI_START="0.4483782603275017" EFFECT_SIZE="7.203476722727368" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0634397666532376" LOG_CI_START="-0.3483554523854607" LOG_EFFECT_SIZE="0.8575421571338884" ORDER="17382" O_E="0.9838187702265373" SE="1.4167004502422085" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="0.4982461323304004" WEIGHT="28.997211935489624"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17383" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17384" O_E="0.0" SE="0.0" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17385" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="17386" O_E="0.5" SE="2.0" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="14.549642262080217"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17387" O_E="0.0" SE="0.0" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17388" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="90.63905415415354" CI_START="0.30093809533786875" EFFECT_SIZE="5.222714267541057" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9573153648851829" LOG_CI_START="-0.5215228320412431" LOG_EFFECT_SIZE="0.7178962664219699" ORDER="17389" O_E="0.7796610169491525" SE="1.4560818273215526" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.4716593375024861" WEIGHT="27.449898520923714"/>
<DICH_DATA CI_END="16.060983432997798" CI_START="0.06226268797124019" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2057721341212484" LOG_CI_START="-1.2057721341212484" LOG_EFFECT_SIZE="0.0" ORDER="17390" O_E="0.0" SE="1.4165530405022932" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="0.49834983498349833" WEIGHT="29.00324728150644"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.198622677394183" CI_END="2.5861826782659194" CI_START="0.103909959262137" DF="3.0" EFFECT_SIZE="0.5183918756530198" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="42.29240731308943" ID="CMP-002.02.07" LOG_CI_END="0.4126591985647858" LOG_CI_START="-0.9833428254427635" LOG_EFFECT_SIZE="-0.28534181343898896" NO="7" P_CHI2="0.1578178159979522" P_Z="0.4229982428999056" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="99.99999999999997" Z="0.8012304681597527">
<NAME>Withdrawals: neurological adverse reactions (headache, dizziness, tingling)</NAME>
<DICH_DATA CI_END="6.603148064025628" CI_START="0.0025971619485302445" EFFECT_SIZE="0.13095588910926653" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8197510356750016" LOG_CI_START="-2.5855009686763806" LOG_EFFECT_SIZE="-0.8828749665006896" ORDER="17391" O_E="-0.5080906148867314" SE="2.000261883625278" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="0.24993454195075457" WEIGHT="16.80635687889421"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17392" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.3504097078895563" CI_START="0.008749051263224264" EFFECT_SIZE="0.1434010286710165" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.37114357221496885" LOG_CI_START="-2.0580390388046306" LOG_EFFECT_SIZE="-0.8434477332948308" ORDER="17393" O_E="-0.9538461538461539" SE="1.4269138903607683" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="0.4911390532544379" WEIGHT="33.025680010979336"/>
<DICH_DATA CI_END="117.69207836199989" CI_START="0.45047026327397854" EFFECT_SIZE="7.281262357928863" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0707472322618763" LOG_CI_START="-0.3463338726588839" LOG_EFFECT_SIZE="0.8622066798014962" ORDER="17394" O_E="0.9848484848484849" SE="1.4198054057748888" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.49606929811648753" WEIGHT="33.35720463340734"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17395" O_E="0.0" SE="0.0" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="17396" O_E="-0.5" SE="2.0" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.25" WEIGHT="16.810758476719098"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17397" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17398" O_E="0.0" SE="0.0" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17399" O_E="0.0" SE="0.0" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="360.8975481068134" CI_START="0.14194886593069175" DF="0.0" EFFECT_SIZE="7.157443515035897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.02.08" LOG_CI_END="2.5573839315266773" LOG_CI_START="-0.8478680728247044" LOG_EFFECT_SIZE="0.8547579293509864" NO="8" P_CHI2="1.0" P_Z="0.3251412939437074" STUDIES="8" TAU2="0.0" TOTAL_1="508" TOTAL_2="476" WEIGHT="100.0" Z="0.983947593239619">
<NAME>Withdrawals: cardiovascular adverse reactions</NAME>
<DICH_DATA CI_END="360.8975481068137" CI_START="0.14194886593069161" EFFECT_SIZE="7.157443515035897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5573839315266773" LOG_CI_START="-0.8478680728247049" LOG_EFFECT_SIZE="0.8547579293509864" ORDER="17400" O_E="0.49190938511326865" SE="2.000261883625278" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="0.24993454195075457" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17401" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17402" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17403" O_E="0.0" SE="0.0" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17404" O_E="0.0" SE="0.0" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17405" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17406" O_E="0.0" SE="0.0" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17407" O_E="0.0" SE="0.0" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="115.72835145257443" CI_START="0.4483782603275017" DF="0.0" EFFECT_SIZE="7.203476722727368" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.02.09" LOG_CI_END="2.0634397666532376" LOG_CI_START="-0.3483554523854607" LOG_EFFECT_SIZE="0.8575421571338884" NO="9" P_CHI2="1.0" P_Z="0.16338510828025626" STUDIES="9" TAU2="0.0" TOTAL_1="539" TOTAL_2="510" WEIGHT="100.0" Z="1.393776494736671">
<NAME>Withdrawals: miscellaneous adverse reactions</NAME>
<DICH_DATA CI_END="115.72835145257443" CI_START="0.4483782603275017" EFFECT_SIZE="7.203476722727368" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0634397666532376" LOG_CI_START="-0.3483554523854607" LOG_EFFECT_SIZE="0.8575421571338884" ORDER="17408" O_E="0.9838187702265373" SE="1.4167004502422085" STUDY_ID="STD-Bombardier-1986" TOTAL_1="157" TOTAL_2="152" VAR="0.4982461323304004" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17409" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17410" O_E="0.0" SE="0.0" STUDY_ID="STD-Glennas-1997" TOTAL_1="31" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17411" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17412" O_E="0.0" SE="0.0" STUDY_ID="STD-Lewis-1984" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17413" O_E="0.0" SE="0.0" STUDY_ID="STD-Palmer-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17414" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17415" O_E="0.0" SE="0.0" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17416" O_E="0.0" SE="0.0" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-09-22 01:01:50 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Adverse reactions not requiring withdrawal</NAME>
<DICH_OUTCOME CHI2="18.042987392750646" CI_END="3.2416224423333873" CI_START="2.0103029008533584" CI_STUDY="95" CI_TOTAL="95" DF="16.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.5527716308542283" ESTIMABLE="YES" EVENTS_1="286" EVENTS_2="153" I2="11.322888767142201" I2_Q="27.02757654968632" ID="CMP-003.01" LOG_CI_END="0.5107624303891611" LOG_CI_START="0.30326149934000113" LOG_EFFECT_SIZE="0.40701196486458113" METHOD="PETO" MODIFIED="2008-09-22 01:01:50 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.321385822745059" P_Q="0.241358644194398" P_Z="1.4838485076009198E-14" Q="5.481522760065063" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1577" TOTAL_2="1361" WEIGHT="500.0" Z="7.688917715964054">
<NAME>Adverse reactions: System specific</NAME>
<GROUP_LABEL_1>Auranofin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="3.6158643813750566" CI_END="4.646009315439129" CI_START="2.087573092261278" DF="4.0" EFFECT_SIZE="3.114303137670764" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="56" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.6670800762433287" LOG_CI_START="0.31964169038798323" LOG_EFFECT_SIZE="0.493360883315656" NO="1" P_CHI2="0.46048098839481155" P_Z="2.6023588355395354E-8" STUDIES="5" TAU2="0.0" TOTAL_1="311" TOTAL_2="284" WEIGHT="100.00000000000001" Z="5.56627938676959">
<NAME>Adverse reaction: gastrointestinal</NAME>
<DICH_DATA CI_END="112.35178503168254" CI_START="0.9465152277569737" EFFECT_SIZE="10.312258501325767" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.050579976828591" LOG_CI_START="-0.023872394613415546" LOG_EFFECT_SIZE="1.0133537911075876" ORDER="17417" O_E="1.5714285714285714" SE="1.2185435916898848" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.673469387755102" WEIGHT="2.805102022199583"/>
<DICH_DATA CI_END="5.279590716800325" CI_START="1.284734324863357" EFFECT_SIZE="2.6043946350550087" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="34" LOG_CI_END="0.7226002565632248" LOG_CI_START="0.10881332753107535" LOG_EFFECT_SIZE="0.4157067920471501" ORDER="17418" O_E="7.363636363636367" SE="0.3605414804077843" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="7.692890038483376" WEIGHT="32.042052387028136"/>
<DICH_DATA CI_END="53.982341742491606" CI_START="1.7706434501493444" EFFECT_SIZE="9.776680409528907" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.7322517202312995" LOG_CI_START="0.24813111724752893" LOG_EFFECT_SIZE="0.9901914187394143" ORDER="17419" O_E="3.0" SE="0.8717797887081348" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="1.3157894736842104" WEIGHT="5.480462483563778"/>
<DICH_DATA CI_END="29.633330614748793" CI_START="1.0358344986584402" EFFECT_SIZE="5.54032726117403" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.4717804664080432" LOG_CI_START="0.01529037118032295" LOG_EFFECT_SIZE="0.7435354187941832" ORDER="17420" O_E="2.3389830508474576" SE="0.8555494916790115" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="1.3661856672485806" WEIGHT="5.690370264153179"/>
<DICH_DATA CI_END="4.699621105061749" CI_START="1.5819047295382158" EFFECT_SIZE="2.7266009706473" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="20" LOG_CI_END="0.6720628454646501" LOG_CI_START="0.19918032449557854" LOG_EFFECT_SIZE="0.4356215849801143" ORDER="17421" O_E="13.0" SE="0.27777353362346346" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="12.96039603960396" WEIGHT="53.98201284305534"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5828125437961287" CI_END="4.471770179666775" CI_START="1.9474286491965742" DF="4.0" EFFECT_SIZE="2.9510088716413563" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="35" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.6504794754983816" LOG_CI_START="0.28946155475134755" LOG_EFFECT_SIZE="0.46997051512486454" NO="2" P_CHI2="0.46539878720601713" P_Z="3.344279313389545E-7" STUDIES="5" TAU2="0.0" TOTAL_1="311" TOTAL_2="284" WEIGHT="100.00000000000001" Z="5.1029338462447456">
<NAME>Adverse reaction: diarrhea</NAME>
<DICH_DATA CI_END="112.35178503168254" CI_START="0.9465152277569737" EFFECT_SIZE="10.312258501325767" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.050579976828591" LOG_CI_START="-0.023872394613415546" LOG_EFFECT_SIZE="1.0133537911075876" ORDER="17422" O_E="1.5714285714285714" SE="1.2185435916898848" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.673469387755102" WEIGHT="3.028660441331502"/>
<DICH_DATA CI_END="4.898418578619669" CI_START="1.0912994174579467" EFFECT_SIZE="2.312064303022913" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.6900558936138399" LOG_CI_START="0.03794392337420933" LOG_EFFECT_SIZE="0.3639999084940246" ORDER="17423" O_E="5.712121212121211" SE="0.3830537993250722" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="6.815228972584975" WEIGHT="30.648778939586"/>
<DICH_DATA CI_END="53.982341742491606" CI_START="1.7706434501493444" EFFECT_SIZE="9.776680409528907" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.7322517202312995" LOG_CI_START="0.24813111724752893" LOG_EFFECT_SIZE="0.9901914187394143" ORDER="17424" O_E="3.0" SE="0.8717797887081348" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="1.3157894736842104" WEIGHT="5.917239299252136"/>
<DICH_DATA CI_END="90.63905415415354" CI_START="0.30093809533786875" EFFECT_SIZE="5.222714267541057" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9573153648851829" LOG_CI_START="-0.5215228320412431" LOG_EFFECT_SIZE="0.7178962664219699" ORDER="17425" O_E="0.7796610169491525" SE="1.4560818273215526" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.4716593375024861" WEIGHT="2.121100087473993"/>
<DICH_DATA CI_END="4.699621105061749" CI_START="1.5819047295382158" EFFECT_SIZE="2.7266009706473" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="20" LOG_CI_END="0.6720628454646501" LOG_CI_START="0.19918032449557854" LOG_EFFECT_SIZE="0.4356215849801143" ORDER="17426" O_E="13.0" SE="0.27777353362346346" STUDY_ID="STD-Wenger-1983" TOTAL_1="152" TOTAL_2="152" VAR="12.96039603960396" WEIGHT="58.284221232356394"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8590911276249886" CI_END="3.8138576864582387" CI_START="1.13255137559008" DF="3.0" EFFECT_SIZE="2.078314165159608" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="36" I2="22.261488501146165" ID="CMP-003.01.03" LOG_CI_END="0.5813644833772618" LOG_CI_START="0.054057911902705466" LOG_EFFECT_SIZE="0.3177111976399836" NO="3" P_CHI2="0.27708730553563" P_Z="0.018185301837508088" STUDIES="4" TAU2="0.0" TOTAL_1="159" TOTAL_2="132" WEIGHT="100.0" Z="2.3618234194128633">
<NAME>Adverse reaction: mucosal / cutaneous</NAME>
<DICH_DATA CI_END="413.3852242568678" CI_START="0.16131764544996868" EFFECT_SIZE="8.166169912567655" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.616354949460138" LOG_CI_START="-0.7923181254664801" LOG_EFFECT_SIZE="0.9120184119968291" ORDER="17427" O_E="0.5238095238095238" SE="2.002271437415744" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.24943310657596368" WEIGHT="2.393071458565344"/>
<DICH_DATA CI_END="4.11039491055748" CI_START="1.0418286398730392" EFFECT_SIZE="2.069378442674796" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="31" LOG_CI_END="0.6138835491842964" LOG_CI_START="0.017796292017641633" LOG_EFFECT_SIZE="0.31583992060096905" ORDER="17428" O_E="5.93181818181818" SE="0.35014460553920396" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="8.1565240363384" WEIGHT="78.25402626142234"/>
<DICH_DATA CI_END="25.24572888433893" CI_START="0.8280704958398422" EFFECT_SIZE="4.572225195142161" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.4021879139848283" LOG_CI_START="-0.08193268899894247" LOG_EFFECT_SIZE="0.6601276124929429" ORDER="17429" O_E="2.0" SE="0.8717797887081348" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="1.3157894736842104" WEIGHT="12.623738196499003"/>
<DICH_DATA CI_END="3.1778129168717584" CI_START="0.02947030442802729" EFFECT_SIZE="0.3060246952053512" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5021283259859477" LOG_CI_START="-1.5306153778681097" LOG_EFFECT_SIZE="-0.5142435259410809" ORDER="17430" O_E="-0.8305084745762712" SE="1.194043713887489" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.7013899630963695" WEIGHT="6.729164083513306"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.025413181356348" CI_START="0.23301099635557404" DF="0.0" EFFECT_SIZE="0.9684862085392355" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="0.6048104643743222" LOG_CI_START="-0.6326235830775963" LOG_EFFECT_SIZE="-0.013906559351637046" NO="4" P_CHI2="1.0" P_Z="0.964862138356036" STUDIES="5" TAU2="0.0" TOTAL_1="160" TOTAL_2="133" WEIGHT="100.0" Z="0.04405302332548971">
<NAME>Adverse reaction: renal</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17431" O_E="0.0" SE="0.0" STUDY_ID="STD-Bombardier-1986" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17432" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.025413181356347" CI_START="0.2330109963555741" EFFECT_SIZE="0.9684862085392355" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6048104643743222" LOG_CI_START="-0.6326235830775961" LOG_EFFECT_SIZE="-0.013906559351637046" ORDER="17433" O_E="-0.06060606060606055" SE="0.7268748848705808" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="1.8926951681982909" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17434" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17435" O_E="0.0" SE="0.0" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="159" TOTAL_2="132" WEIGHT="0.0" Z="0.0">
<NAME>Adverse reaction: liver</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17436" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17437" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17438" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17439" O_E="0.0" SE="0.0" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="159" TOTAL_2="132" WEIGHT="0.0" Z="0.0">
<NAME>Adverse reaction: hematology</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17440" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17441" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17442" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17443" O_E="0.0" SE="0.0" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="159" TOTAL_2="132" WEIGHT="0.0" Z="0.0">
<NAME>Adverse reaction: neurological</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17444" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17445" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17446" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17447" O_E="0.0" SE="0.0" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.50369657988941" CI_END="3.1279978827016297" CI_START="0.8312637315254077" DF="1.0" EFFECT_SIZE="1.6125108347475159" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="22" I2="33.49722188810555" ID="CMP-003.01.08" LOG_CI_END="0.4952664504200003" LOG_CI_START="-0.08026116758182295" LOG_EFFECT_SIZE="0.2075026414190886" MODIFIED="2008-09-22 01:01:50 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.22010383737245365" P_Z="0.15756639764982766" STUDIES="4" TAU2="0.0" TOTAL_1="159" TOTAL_2="132" WEIGHT="100.0" Z="1.413303866425589">
<NAME>Adverse reaction: miscellaneous</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17448" O_E="0.0" SE="0.0" STUDY_ID="STD-Davies-1982" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.817484383704897" CI_START="0.693722547777572" EFFECT_SIZE="1.3980530909043773" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" LOG_CI_END="0.4498615175878562" LOG_CI_START="-0.15881418957681462" LOG_EFFECT_SIZE="0.14552366400552075" ORDER="17449" O_E="2.621212121212121" SE="0.3575391233818711" STUDY_ID="STD-Johnsen--1989" TOTAL_1="67" TOTAL_2="65" VAR="7.822631239529227" WEIGHT="89.40471028140033"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17450" O_E="0.0" SE="0.0" STUDY_ID="STD-Prouse-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="41.16677968902816" CI_START="0.7021582133835045" EFFECT_SIZE="5.376392143175604" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.6145468952222701" LOG_CI_START="-0.15356501969685768" LOG_EFFECT_SIZE="0.7304909377627063" ORDER="17451" O_E="1.559322033898305" SE="1.0385976911186299" STUDY_ID="STD-Ward-1983" TOTAL_1="72" TOTAL_2="46" VAR="0.9270545599186796" WEIGHT="10.595289718599672"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>